WO2013128029A1 - Dérivés pyrazolo-triazine pharmaceutiquement actifs - Google Patents

Dérivés pyrazolo-triazine pharmaceutiquement actifs Download PDF

Info

Publication number
WO2013128029A1
WO2013128029A1 PCT/EP2013/054225 EP2013054225W WO2013128029A1 WO 2013128029 A1 WO2013128029 A1 WO 2013128029A1 EP 2013054225 W EP2013054225 W EP 2013054225W WO 2013128029 A1 WO2013128029 A1 WO 2013128029A1
Authority
WO
WIPO (PCT)
Prior art keywords
pyrazolo
isopropyl
ethyl
triazin
methoxyphenyl
Prior art date
Application number
PCT/EP2013/054225
Other languages
English (en)
Inventor
Jan Eickhoff
Gunther Zischinsky
Uwe Koch
Gerd Rühter
Carsten Schultz-Fademrecht
Peter Nussbaumer
Original Assignee
Lead Discovery Center Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lead Discovery Center Gmbh filed Critical Lead Discovery Center Gmbh
Priority to US14/389,946 priority Critical patent/US9096608B2/en
Publication of WO2013128029A1 publication Critical patent/WO2013128029A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Definitions

  • the present invention relates to pyrazolo[1 ,5-a][1 ,3,5]triazine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of cell proliferative diseases, inflammatory and immunological diseases, cardiovascular diseases and infectious diseases. Furthermore, the present invention is directed towards pharmaceutical composition containing at least one of the pyrazolo[1 ,5- a][1 ,3,5]triazine derivatives and/or pharmaceutically acceptable salts thereof.
  • CDK family members that trigger passage through the cell cycle are being considered as attractive therapeutic targets, especially for cancer.
  • CDK family members that control other processes such as transcription and RNA processing have caught less attention so far, although experimental evidence for their involvement in different pathological processes is emerging.
  • the CDK-activating kinase, or CAK complex consists of CDK7, cyclin H, and MAT1 .
  • CDK7 phosphorylates other CDKs, an essential step for their activation. Therefore CDK7 is required for cell cycle progression, which suggests that CDK7 is a target for cancer therapy.
  • CDK7 participates in basal transcription by phosphorylating the carboxy-terminal domain of the largest subunit of RNA polymerase II.
  • CDK7 is a therapeutic target for treatment of diseases like inflammation, virus replication such as HIV, EBV, and HCV, cancer and cardiac hypertrophy.
  • HIV-1 gene expression is regulated by a viral transactivator protein (Tat) which induces transcriptional elongation of HIV-1 long tandem repeat. This induction requires hyperphosphorylation of the C-terminal domain repeats of RNA polymerase II.
  • Tat viral transactivator protein
  • Tat stimulates CTD kinases associated with general transcription factors of the promoter complex, specifically TFIIH-associated CDK7.(Nekhai et al.; Biochem. J. (2002) 364, 649-657). Also the inventors of US 615968 describe that Tat binds to CDK7 and that this interaction increases the ability of CAK to phosphorylate CTD. The authors of US 615968 further disclose that the transcriptional activation by Tat is dependent upon the kinase activity of CDK07. Additionally, Young Kyeung Kim and colleagues conclude that the recruitment and activation of TFIIH represents a rate-limiting step for the emergence of HIV from latency (Young Kyeung Kim, EMBO I (2006) 25, 3596-3604).
  • MAT- 1 /cyclin H are upregulated during Human cytomegalovirus infection.
  • kinase activities of CDK7 and CDK9 Troprakar et al., Journal of Virology, 2005, 79; 15477-15493.
  • antiviral drugs target viral proteins. These have the disadvantage that viruses often develop resistance against these drugs. Antiviral drugs targeting cellular proteins essential for viral process, like CDK7, could bypass this disadvantage. These drugs may further be effective in treating several unrelated viruses and their effects should be additive to traditional antiviral agents. Inhibitors of CDK7, which has its dual function of CDK-activating kinase and transcription regulation is very effective in the treatment of several viruses.
  • R 1 represents Ci-C 4 -alkyl, cydopropyl, 1 -methylcyclopropyl, or cydobutyl;
  • R 2 represents -R 8 , -Q-R 8 , -R 9 , -Q-(CH 2 ) n -R 9 , -(CH 2 ) n -R 9 , -(CH 2 ) n -NH-R 8 , -(CH 2 ) m -NH-(CH 2 ) n -R 9 , -CO-NH-(CH 2 )n-NH 2 , -CO-NH-(CH 2 ) n -R 9 , -CO-R 9 , -SO-R 9 , -(CH 2 )n-NR 10 -R 8 , -(CH 2 ) m -NR 10 -(CH 2 )n-R 9 , -CO-NR 10 -(CH 2 ) n -
  • heterocydyl 4-membered heterocydyl, 5-membered heterocydyl, 6- membered heterocydyl, monounsaturated 4-membered heterocydyl, monounsaturated 5-membered heterocydyl, monounsaturated 6-membered heterocydyl, 3-membered carbocyclyl, 4-membered carbocyclyl, 5-membered carbocyclyl, 6-membered carbocyclyl, 6-membered aryl, 5-membered heteroaryl, 6-membered heteroaryl, and wherein all afore-mentioned ring systems can be substituted with 1 to 4 substituents selected from Z 1 , Z 2 , Z 3 and Z 4 ;
  • R 3 together with R 4 or R 4 together with R 5 can form a carbocylic or heterocyclic 4-, 5-, 6- or 7-membered ring with the two carbon atoms of the benzo ring to which R 3 and R 4 are attached and that 4-, 5-, 6- or 7-membered ring can be partly saturated or unsaturated and can be substituted with 1 to 4 substituents selected from Z 1 , Z 2 , Z 3 and Z 4 ;
  • R 4 - R 7 represent independently of each other -H, -F, -CI, -Br, -CrC 4 -alkyl, -O-Ci-C 4 -alkyl, -O-cyclopropyl, -O-1 -methylcyclopropyl, -O-cyclobutyl, -O-nitrogenheteroaryl;
  • R 9 represents -R 8 , nitrogenheterocyclyl, spironitrogencyclyl, wherein the afore- mentioned nitrogenheterocyclyl and spironitrogencyclyl residues are linked through a ring nitrogen atom and can be substituted with 1 to 3 substituents selected from Z 5 , Z 6 and Z 7 ;
  • R 11 , R 12 , R 13 , R 14 and R 15 represent independently of each other
  • Ci-Cs-alkyl linear or branched Ci-Cs-alkyl, Cs-Cs-cycloalkyl, Ci-Cg-heterocyclyl, linear or branched C2-Cs-alkenyl, linear or branched C2-Cs-alkynyl, C6-Ci 4 -aryl, Ci-Cio-heteroaryl,
  • R , R and R represent independently of each other — H, -CH3, -C2H 5 , -C3H 7 , -CH(CH3)2, -CH2F, -CHF2, -CF3, cyclo-C3H 5 , cyclo-C 4 H 7 , cyclo-C 5 H 9 , cyclo-CeHn, cyclo-C 7 Hi 3 ,
  • b, d, f are independently of each other 0 or 1
  • n is an integer selected from 1 , 2, 3, 4, 5, 6, 7 or 8,
  • n is an integer selected from 0, 1 , 2, 3, 4, 5 or 6,
  • p is an integer selected from 1 , 2, 3, 4, 5, 6, 7 or 8 and enantiomers, stereoisomeric forms, mixtures of enantiomers, diastereomers, mixtures of diastereomers, hydrates, solvates, acid salt forms, tautomers, and racemates of the above mentioned compounds and pharmaceutically acceptable salts thereof.
  • Prodrugs of the compounds related to formula (I) are also within the scope of this invention. These derivatives may have little or no pharmacological activity themselves.
  • the term "prodrug” as used herein describes a precursor of the active ingredient according to general formula (I), wherein said precursor comprises groups which can be cleaved under physiological conditions so that the active agent of formula (I) is formed. Information on the use of prodrugs may be found for example in "Pro-drugs as Novel Drug Delivery Systems” by T. Higuchi and W. Stella, ACS Symposium Series Vol. 14, 1975( ISBN13: 9780841202917).
  • prodrugs for example by replacing a functional group in the compounds according to formula (I) with certain moieties.
  • Examples for prodrugs of a compound according to formula (I) containing a primary or secondary amino functionality include but are not limited to moieties like amides, carbamates or alkyl derivatives thereof. More information on the use of prodrugs for amines may be found for example in Molecules 2008, 13, 519-547 (A.L. Simplicio et al.) or "Prodrugs of Amines" by J. P. Krise and R. Oliyai (Biotechnology: Pharmaceutical Aspects, 2007, Volume V, Part III, 801 -831 ).
  • tautomer is defined as an organic compound that is interconvertible by a chemical reaction called tautomerization. Tautomerization can be catalyzed preferably by bases or acids or other suitable compounds. Preferred are compounds of general formula (I), wherein
  • R 1 represents -CH 3 , cyclopropyl, 1 -methylcyclopropyl, or cyclobutyl,
  • R 3 represents -H, -CH 3 , -OH, -NH 2 , -F, -CI, -Br, -I, -CN, -OR 11 , -NO 2 , -CO-O-R 1 1 , -CH 3 , -NR 1 1 -CO-OR 12 , -NHR 11 , -NR 11 R 12 , -CONR 1 1 R 12 , -O-CO-NR 11 R 12 , -O-CO-OR 11 , -NR 11 -CO-NR 12 R 13 , -SO 2 NR 1 1 R 12 ,
  • R represents 4-membered nitrogenheterocyclyl, 5-membered nitrogenheterocyclyl, 6- membered nitrogenheterocyclyl, 5-membered dinitrogenheterocyclyl, 6-membered dinitrogenheterocyclyl spiro[2,3]heterohexyl spiro[2,4]heteroheptyl sp i ro [2 , 5] h eteroocty I , spiro[2,7]heterononyl, spiro[3,3]heteroheptyl spiro[3,4]heterooctyl, spiro[3,5]heterononyl, spiro[3,6]heterodecyl spiro[4,4]heteronony
  • R 1 represents -CH 3 , cyclopropyl, 1 -methylcyclopropyl, or cyclobutyl;
  • R 2 represents -R 8 , -Q-R 8 , -R 9 , -Q-(CH 2 ) n -R 8 , -Q-(CH 2 ) n -R 9 , -(CH 2 ) n -R 9 , -(CH 2 )n-NH-R 8 , -(CH 2 ) m -NH-(CH 2 ) n -R 9 , -CO-NH-(CH 2 ) n -NH 2 ,
  • R 1 being a residue different from hydrogen is essential in order to obtain the desired activity and selectivity of the compounds of general formula (I). Consequently, the possibility that R 1 is hydrogen is excluded from the scope of the present invention.
  • the other substituents R 3 - R 7 can be hydrogen or any other of the substituents defined herein for these groups.
  • R 1 represents -CH 3 , -CH 2 CH 3 or cyclopropyl.
  • R 2 represents preferably a moiety containing a group able to form hydrogen bridges such as -NH 2 , or a secondary or tertiary amino group [such as -NH-(carbon linked substituent), -N(carbon linked substituent1 )(carbon linked substituent2) , -NH-(sulfur linked substituent) or -N(sulfur linked substituent1 )(carbon linked substituent2)], wherein the carbon or sulfur linked substituents are the Ci-Cs-alkylamines, carbocyclyl, heterocyclyl, nitrogenheterocyclyl, spirocarbocyclyl, spiroheterocyclyl, Ci-Cs-alkyl, Cs-Cs-cycloalkyl, Ci-Cs-fluoroalkyl, C6-Ci 4 -aryl, C 7 -C 2 o-alkylaryl, Cs-C 2 o-alkenylaryl, C 2 -Cs-alkenyl,
  • the group which is able to form hydrogen bridges is preferably linked through a linker to the pyrazolo[1 ,5- a][1 ,3,5]triazine ring system.
  • the group which is able to form hydrogen bridges is further preferably attached to a carbocyclic or heterocyclic ring.
  • residues are aminocydohexyl, aminocydopentyl, aminocydobutyl, aminopiperidinyl, or an amino spiro residue, amino azaspiro residue, amino diazaspiro residue, amino triazaspiro residue, amino oxazaspiro residue or amino oxadiazaspiro residue.
  • R 2 represents -Q-R 8 , -R 9 , -Q-(CH 2 ) n -R 9 , -(CH 2 ) n -R 9 , -(CH 2 ) n -NH-R 8 , -(CH 2 ) n -NH-(CH 2 ) m -R 9 , -CO-NH-R 8 , -CO-R 9 ,
  • R 2 represents -Q-R 8 , -R 9 , -Q-(CH 2 ) n -R 9 , -(CH 2 ) n -R 9 , -(CH 2 ) n -R 9 , -(CH 2 ) n -NH-R 8 , -(CH 2 ) n -NH-(CH 2 ) m -R 9 , -CO-NH-R 8 , -CO-R 9 , -(CH 2 ) n -NR 15 -R 8 , or -(CH 2 ) n n , and it is more preferred that R 2 represents -Q-R 8 , -R 9 , -Q-(CH 2 ) n -R 9 , -(CH 2 ) n -R 9 , -(CH 2 ) n -NH-R 8 , -(CH 2 ) n -NH-(CH 2 ) m -R 9
  • n is an integer selected from 1 , 2, 3, 4, 5, 6, 7 or 8,
  • n is an integer selected from 0, 1 , 2, 3, 4, 5 or 6.
  • Q represents preferably -O-, -S-, -NR 15 -, -SO-, -NR 15 -SO- -SO-NR 15 -, -SO 2 -, -O-SO 2 -, -SO 2 -O- -SO 2 -NR 15 -, -NR 15 -SO 2 - -O-CO-, -O-CO-O-, -CO-, -CO-NR 15 -, -NR 15 -CO- -NR 15 -CO-NR 15 -, -NR 15 -CO-O- -O-CO-NR 15 -, -CO-O-, -(CH 2 ) m -NR 15 -, bridging carbocyclyl, bridging heterocyclyl, bridging spirocarbocyclyl, bridging spiroheterocyclyl;
  • n is an integer selected from 1 , 2, 3, 4, 5, 6, 7 or 8,
  • n is an integer selected from 0, 1 , 2, 3, 4, 5 or 6,
  • Q represents -O-, -S-, -NR 15 -, -SO-, -SO 2 - -O-CO-, -CO-, -CO-NR 15 -, -NR 15 -CO- -CO-O-, -(CH 2 ) m -NR 15 -, and even more preferably Q represents -O-, -S-, -NR 15 -, -SO-, -SO 2 - -(CH 2 ) m -NR 15 -, and most preferably Q represents -O-, -NH-, -SO-, -CO-NR 15 - or -(CH 2 ) m -NR 15 -.
  • the substituent -Q-R 10 represents preferably -S-R 10 . More preferably -R 10 in -S-R 10 is selected from -CH 3 , -C 2 H 5 , -C 3 H 7 , -CH(CH 3 ) 2 , -CH 2 F, -CHF 2 , -CF 3 , cyclo-C3H 5 , cyclo-C 4 H 7 , cyclo-C 5 H 9 , cyclo-CeHn, cyclo
  • R 2 represents a linking moiety -(CH2)a-(Q)b-(CH2)c-(G 1 )d-(CH2)e-(G 2 )f-(CH 2 )g-R 8 or -(CH2)a-(Q)b-(CH2)c-(G 1 )d-(CH2)e-(G 2 )f-CH2-R 9 , with R 8 and R 9 as defined herein and Q is defined as discloses herein and G 1 and G 2 represent independently of each other:
  • piperidindiyl piperazindiyl, pyrimidindiyl, morpholindiyl, pyridazindiyl, pyrrol id indiyl, pyrazolidinyl,
  • At least G 1 or G 2 represents independently one of the following linking structures, wherein the lines are not methyl groups and indicate the linking bonds:
  • a, c, e, g are independently of each other selected from 0, 1 , 2, 3
  • b, d, f are independently of each other 0 or 1
  • n is an integer selected from 1 , 2, 3, 4, 5, 6, 7 or 8,
  • n is an integer selected from 0, 1 , 2, 3, 4, 5 or 6,
  • p is an integer selected from 1 , 2, 3, 4, 5, 6, 7 or 8;
  • -SO( NR 11 )-R 12 , -CO-R 11 , -O-CO-R 11 , -NR 1 1 -CO-R 12 , 3-membered heterocyclyl, 4-membered heterocyclyl, 5-membered heterocyclyl, 6- membered heterocyclyl, monounsaturated 4-membered heterocyclyl, monounsaturated 5-membered heterocyclyl, monounsaturated 6-membered heterocyclyl, 3-membered carbocyclyl, 4-membered carbocyclyl, 5-membered carbocyclyl, 6-membered carbocyclyl, 6-membered aryl, 5-membered heteroaryl, 6-membered heteroaryl,
  • Z 5 and Z 6 or where Z 8 and Z 9 can form together a carbonyl group.
  • the residue R 3 preferably represents independently of each other -OR 1 1 , -F, -CI, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, imidazolyl, furyl, dihydrofuryl, tetrahydrofuryl, thienyl, dihydrothienyl, tetrahydrothienyl, 1 ,3-oxazolyl, dihydro-1 ,3-oxazolyl, 1 ,3-oxazolidinyl, isoxazolyl, dihydro-isoxazolyl, isoxazolidinyl, pyrrolyl, dihydropyrrolyl, pyrrolidinyl, imidazolyl, dihydroimidazolyl, imidazolidinyl, triazolyl, dihydrotriazolyl, triazolidinyl, pyrazolyl,
  • the afore-mentioned ring systems can be substituted with one to three substituents selected from Z 1 , Z 2 and Z 3 and most preferably the afore-mentioned ring systems can be substituted with one or two substituents selected from Z 1 and Z 2 .
  • OR 1 1 is preferably selected from -OCH3, -OC 2 H 5 , and, -OCF3,
  • -CZ 8 CZ 9 -CZ 10 Z 11 -O-, -CO-CZ 8 Z 9 -CZ 10 Z 11 -, -CZ 8 Z 9 -CO-CZ 10 Z 11 -
  • R 11 and R 12 are joined together, they form a ring system and especially a four- membered, a five-membered or a six-membered ring system together with the atoms to which they are attached.
  • Preferred ring systems are five-membered cyclocarbamates, five-membered cyclic ureas, five-membered cyclic guanidines, six-membered cyclocarbamates, six-membered cyclic ureas, six-membered cyclic guanidines, pyrrolidones, pyridones, piperidinones, imidazoles, imidazolines, pyrrolines, imidazolidin-2-ones.
  • R 3 together with R 4 can form a carbocylic or heterocyclic 4-, 5-, 6- or 7-membered ring with the two carbon atoms of the benzo ring to which R 3 and R 4 are attached and that 4-, 5-, 6- or 7-membered ring can be partly saturated or unsaturated and can be substituted with 1 to 4 substituents selected from Z 1 , Z 2 , Z 3 and Z 4 .
  • Partly saturated as used herein means that the ring system additionally formed by joining R 3 with R 4 when taken alone already bears one double bond originated in the phenyl ring to which R 3 and R 4 are attached.
  • R 3 and R 4 are attached to a phenyl ring a double bond equivalent exists between the two carbonatoms that bear R 3 and R 4 , respectively. Therefore, the preson skilled in the art will understand that the ring system formed when R 3 and R 4 are joined together can not be a saturated ring system, but a partly saturated ring system when the moiety introduces at least one saturated atom or two subsequent saturated bonds.
  • R 10 , R 16 and R 17 are selected from the following group of substituents: -H, -CH3, -C2H 5 , -C3H 7 , -CF3, cyclo-C 3 H 5 , cyclo-C 4 H 7 , cyclo-C 5 H 9 , cyclo-CeHn , cyclo
  • R 4 - R 7 represent independently of each other -H, -F, -CI, -OCH3, -CH 3 ; preferably -H or -F.
  • R 3 is hydrogen, it is particularly preferred that R 4 -R 7 represent hydrogen as well or that R 5 -R 7 represent hydrogen and R 4 represents a residue different from hydrogen, preferably -CI or -OCH3.
  • R 8 represents preferably -(CH 2 ) P -NH 2 , -(CH 2 ) P -N(R 16 R 17 ), C 3 -C 8 -cycloalkyl, C 7 -Ci6-spiroalkyl, Ci-C 9 -heterocyclyl, C 5 -Ci 4 -spiroheterocyclyl, wherein the afore-mentioned residues are linked through a ring carbon atom and can be substituted with 1 to 3 substituents selected from Z 5 , Z 6 and Z 7 ;
  • R 8 represents more preferably Cs-Cs-cycloalkyl, substituted Cs-Cs-cycloalkyl, C 7 -Ci6-spiroalkyl, substituted C 7 -Ci6-spiroalkyl, Ci-C 9 -heterocyclyl, substituted Ci-C 9 -heterocyclyl, C 5 -Ci 4 -spiroheterocyclyl, substituted C 5 -Ci 4 -spiroheterocyclyl, wherein the afore-mentioned substituted residues are linked through a ring carbon atom and can be substituted with 1 to 3 substituents selected from Z 5 , Z 6 and Z 7 ,
  • R 8 represents most preferably piperidinyl, morpholinyl, piperazinyl, pyranyl, pyrrolidinyl, iminopropylenyl, pyridyl and cyclohexyl, wherein the afore-mentioned substituted residues are linked through a ring carbon atom and can be substituted with 1 to 3 substituents selected from Z 5 , Z 6 and Z 7 .
  • R 9 represents preferably -R 8 , Ci-Cg-nitrogenheterocyclyl, C 5 -Ci 4 - spironitrogenheterocyclyl, wherein the afore-mentioned nitrogenheterocyclyl and spironitrogencyclyl residues are linked through a ring nitrogen atom and can be substituted with 1 to 3 substituents selected from Z 5 , Z 6 and Z 7 .
  • R 9 represents more preferably Ci-Cg-nitrogenheterocyclyl, substituted C1-C9- nitrogenheterocyclyl, C 5 -Ci 4 -spironitrogenheterocyclyl, substituted C 5 -Ci 4 - spironitrogenheterocyclyl, wherein the afore-mentioned nitrogenheterocyclyl and spironitrogencyclyl residues are linked through a ring nitrogen atom and can be substituted with 1 to 3 substituents selected from Z 5 , Z 6 and Z 7 .
  • R 9 represents most preferably piperidinyl, morpholinyl, piperazinyl, pyrrolidinyl and iminopropylenyl, wherein the afore-mentioned nitrogenheterocyclyl and spironitrogencyclyl residues are linked through a ring nitrogen atom and can be substituted with 1 to 3 substituents selected from Z 5 , Z 6 and Z 7 .
  • substituent R 2 represents -Q-(CH 2 ) n -R 8 , -(CH 2 ) m -NH-(CH 2 ) n -R 8 , -(CH 2 ) m -NH-(CH 2 ) n -R 9 , -Q-(CH 2 ) n -R 8 , -(CH 2 ) n -R 8 , -CO-NH-(CH 2 ) n -R 8 , -(CH 2 ) m -NR 10 -(CH 2 ) n -R 8 , -CO-NR 10 -(CH 2 ) n -R 8 , -R 8 , -Q-R 8 , -R 9 , -Q-(CH 2 ) n -R 9 , _(CH 2 ) n -R 9 , -(CH 2 ) n -NH-R 8 , -(CH(CH 2 ) m
  • R 11 , R 12 , R 13 , R 14 and R 15 represent independently of each other
  • Ci-Cs-alkyl linear or branched Ci-Cs-alkyl, Cs-Cs-cycloalkyl, Ci-Cg-heterocyclyl, linear or branched C 2 -Cs-alkenyl, linear or branched C 2 -Cs-alkynyl, C6-Ci 4 -aryl, Ci-Cio-heteroaryl, wherein the afore-mentioned residues can be substituted with 1 to 5 substituents selected from Z 8 , Z 9 , Z 10 , Z 11 and Z 12 .
  • R 11 , R 12 , R 13 , R 14 and R 15 preferably represent independently of each other -H, methyl, isopropyl and pyrrol id inyl.
  • Ci-C 4 -alkyl refers to -CH 3 , -CF 3 , -C 2 H 5 , -C 3 H 7 , -C 4 H 9 , -CH(CH 3 ) 2 , -CH 2 -CH(CH 3 ) 2 , -CH(CH 3 )-C 2 H 5 , -C(CH 3 ) 3 , -C 2 F 5 , wherein these residues can be substituted with 1 , 2 or 3 substituents selected from Z 8 , Z 9 and Z 10 .
  • the term "can be substituted” refers to the replacement of a hydrogen atom by one of the substituents Z 8 , Z 9 and Z 10 .
  • linear Ci-Ce-alkyl refers to -CH 3 , -C 2 H 5 , -C 3 H 7 , -C 4 H 9 , -C 5 Hn, -C6Hi 3 , -C 7 Hi 5 , -C8Hi 7 , -CH 2 -Ph, -CH 2 -CH 2 -Ph, wherein these residues can be substituted with 1 to 5 substituents selected from Z 8 , Z 9 , Z 10 , Z 11 and Z 12 .
  • the term "can be substituted” refers to the replacement of a hydrogen atom by one of the substituents Z 8 , Z 9 , Z 10 , Z 11 or Z 12 .
  • substituted as used herein further indicates that the substituted residue like "substituted linear Ci-Cs-alkyl” does definitely have at least one substituent (at least one Z substituent) while the residue without the term “substituted” like "linear Ci-Cs-alkyl” can have at least one substituent. Consequently, if the term “substituted” is not used in relation to a residue this does not indicate that this residue is unsubstituted.
  • Ci-Cs-alkyl residues are -CH 2 -OH, -CH 2 -O-CH 3 , -CH 2 -OCF 3 , -CF 3 , -CH 2 CI, -CH 2 CH 2 CI, -CH 2 CH 2 -OCF 3, and -CH 2 -Ph.
  • Ci-Ce-alkyl or preferably branched C 3 -Cs-alkyl refers to -CH(CH 3 ) 2 , -CH 2 -CH(CH 3 ) 2 , -CH(CH 3 )-C 2 H 5 , -C(CH 3 ) 3 , -CH(CH 3 )-C 3 H 7 , -CH 2 -CH(CH 3 )-C 2 H 5 , -CH(CH 3 )-CH(CH 3 )2, -C(CH 3 )2-C 2 H 5 , -CH 2 -C(CH 3 ) 3 -CH(C 2 H 5 ) 2 , -C 2 H 4 -CH(CH 3 ) 2 , -C 3 H 6 -CH(CH 3 ) 2 , -C 2 H 4 -CH(CH 3 )-C 2 H5 -CH(CH 3 )-C 4 H 9 , -CH 2 -CH(CH 3 ) 2 ,
  • Examples of preferred substituted branched Ci-Cs-alkyl or preferably branched Cs-Cs-alkyl residues are -CH(CH 2 CI) 2 , -CH(CH 3 )-C 2 H 4 -OCF 3 , -C(CH 3 )2-CF 3 , -COCH 3 (CH 3 )2- -CHCH 3 CI, -CH 2 -CHCH 3 NH 2 , -CCICH 3 -C 2 H 5 , -C(CH 3 ) 2 OH, -CCICH 3 -C 3 H 7 , -CH2-C(OH)(CH 3 )-C 2 H 5j -CH(CH 3 )-CHCH 3 CI,
  • Cs-Ce-cycloalkyl refers to CVCI0-C3H 5 , cyclo-C 4 H 7 , cyclo-C 5 H 9 , cyclo-C6Hii , cyclo-C 7 Hi 3 , and cyclo-CsHi 5 , wherein these residues can be substituted with 1 to 5 substituents selected from Z 8 , Z 9 , Z 10 , Z 1 1 and Z 12 .
  • the term "can be substituted” refers to the replacement of a hydrogen atom by one of the substituents Z 8 , Z 9 , Z 10 , Z 1 1 or Z 12 .
  • the carbon atom number of C3-C8 refers only to the carbon atoms of the cydoalkyi residue and does not include the carbon atoms of the substituents Z 8 to Z 12 .
  • the vinyl group has only three hydrogen atoms, only three hydrogen atoms can be replaced by three substituents selected from Z 8 , Z 9 , Z 10 , Z 1 1 and Z 12 .
  • the carbon atom number of C2-C8 refers only to the carbon atoms of the alkenyl residue and does not include the carbon atoms of the substituents Z 8 to Z 12 .
  • -CH(CH 3 )-C 2 H 4 -C ⁇ CH, -CH 2 -CH(CH 3 )-C ⁇ C-CH 3 , -CH(CH 3 )-CH 2 -C ⁇ C-CH 3 , -CH(CH 3 )-C ⁇ C-C 2 H 5 , -CH 2 -C ⁇ C-CH(CH 3 ) 2 , -C ⁇ C-CH(CH 3 )-C 2 H 5 ,
  • Examples of preferred substituted linear or branched C2-C8-alkynyl residues are -C ⁇ C-OH, -C ⁇ C-CI, -C ⁇ C-NH 2 , -C ⁇ C-CF 3 , -C ⁇ C-CH 2 CI, -C ⁇ C-CHCI 2 , -C ⁇ C-CCI 3 , -C ⁇ C-CF 3 , -CH2-C ⁇ C-CO-CH 3 ,
  • the term "Ci-Cg-heterocyclyl” covers saturated or partly unsaturated heterocyclic residues with 1 to 9 ring carbon atoms, but not aromatic residues and covers also bicyclic saturated or partly unsaturated residues with 1 to 9 ring carbon atoms, but preferably not fully aromatic residues which are aromatic throughout the bicyclic system but may comprise partly aromatic ring systems, wherein one ring of the bicyclic ring system is aromatic.
  • Ci-Cg-heterocyclyl refers to
  • the oxirane group (also named as ethylene oxide group) has only three hydrogen atoms, only three hydrogen atoms can be replaced by three substituents selected from Z 8 , Z 9 , Z 10 , Z 11 and Z 12 .
  • the carbon atom number of C1-C9 refers only to the carbon atoms of the heterocyclic ring system (heterocyclyl) and does not include the carbon atoms of the substituents Z 8 to Z 12 .
  • heterocyclyl refers to Ci-Cg-heterocyclyl, 3-membered heterocyclyl, 4-membered heterocyclyl, 5-membered heterocyclyl, 6-membered heterocyclyl, monounsaturated 4-membered heterocyclyl, monounsaturated 5- membered heterocyclyl, and monounsaturated 6-membered heterocyclyl.
  • nitrogenheteroaryl refers to 6-membered aromatic residues with one, two or three nitrogen atoms and preferably to the following groups: 40
  • the oxadiazole group has only one hydrogen atom, only one hydrogen atom can be replaced by one substituent selected from Z 8 , Z 9 , Z 10 , Z 11 and Z 12 .
  • the carbon atom number of C1-C10 refers only to the carbon atoms of the heteroaromatic ring system (heteroaryl) and does not include the carbon atoms of the substituents Z 8 to Z 12 .
  • C6-C -aryl refers to aromatic residues or more specific to aromatic carbocyclic residues with one, two or three aromatic rings and refers preferably to phenyl and naphthyl, wherein these phenyl and naphthyl residues can be substituted with 1 to 5 substituents selected from Z 8 , Z 9 , Z 10 , Z 11 and Z 12 .
  • can be substituted refers to the replacement of a hydrogen atom by one of the substituents Z 8 , Z 9 , Z 10 , Z 11 or Z 12 .
  • the carbon atom number of C6-C14 refers only to the carbon atoms of the aromatic ring system (aryl) and does not include the carbon atoms of the substituents Z 8 to Z 12 .
  • C 7 -Ci6-spiroalkyl refers to spirocarbocyclic residues, wherein these spirocarbocyclic residues can be substituted with 1 to 3 substituents selected from Z 5 , Z 6 and Z 7 .
  • can be substituted refers to the replacement of a hydrogen atom by one of the substituents Z 5 , Z 6 and Z 7 . It is also possible that two of the substituents Z 5 , Z 6 and Z 7 represent together an oxygen atom and form together with the carbon atom of the spiroalkyi residue to which they are both attached a carbonyl moiety.
  • the carbon atom number of C7-C16 refers only to the carbon atoms of the spiro ring system and does not include the carbon atoms of the substituents. Thus a spiro[4,5]decyl residue is counted as a Cio-spiroalkyl regardless if this spiro residue carries five pentyl substituents.
  • preferred substituents Z 5 , Z 6 and Z 7 are -CH 3 , -C2H5, -C3H7, -CH(CH 3 ) 2 , -OH, -OCH3, -OC2H5, -OC3H7, -NH 2 , -N(CH 3 ) 2 , -F, -CI, -Br, -I, -CN, -CH 2 F, -CHF 2 , -CF 3 , -OCHF 2 , -OCF3.
  • Cs-Cu-spiroheterocyclyl refers to spiro residues with one, two or three heteroatoms such as O, S, N in the spiro ring system, wherein these spiroheterocyclic residues can be substituted with 1 to 3 substituents selected from Z 5 , Z 6 and Z 7 .
  • can be substituted refers to the replacement of a hydrogen atom by one of the substituents Z 5 , Z 6 and Z 7 .
  • the carbon atom number of C 5 -C14 refers only to the carbon atoms of the spiro ring system and does not include the carbon atoms of the substituents.
  • a azaspiro[4,5]decyl residue is counted as a Cg-spiroalkyl regardless if this azaspiro[4,5]decyl residue carries five isopropyl substituents.
  • Examples of preferred C 5 -Ci 4 -spiroheterocyclyl groups and substituted C 5 -Ci 4 - spiroheterocyclyl groups are
  • Y and X represent independently of each other -O-, -NH-, -NR 11 -, -SO-, or -SO2-, preferably -NH- and -NR 11 - and Z 5 and Z 6 represent independently of each other -CH 3 , -C 2 H 5 , -C 3 H 7 , -CH(CH 3 ) 2 , -OH, -OCH 3 , -OC 2 H 5 , -OC 3 H 7 , -NH 2 , -N(CH 3 ) 2j -F, -CI, -Br, -I, -CN, -CH 2 F, -CHF 2 , -CF 3 , -OCHF 2 , or -OCF 3 .
  • 3-membered heterocyclyl refers to a substituted or non substituted ring system of three atoms including at least one heteroatom such as O, S, SO, SO 2 , N, NO, wherein these 3-membered heterocyclic residues can be substituted with 1 to 4 substituents selected from Z 1 , Z 2 , Z 3 and Z 4 .
  • can be substituted refers to the replacement of a hydrogen atom by one of the substituents Z 1 , Z 2 , Z 3 or Z 4 .
  • two of the substituents Z 1 , Z 2 , Z 3 and Z 4 represent together an oxygen atom and form together with the ring carbon atom of the heterocyclic ring to which they are both attached a carbonyl moiety or a sulfoxide moiety together with the ring sulphur atom to which they are attached or both Z substituents represent oxygen and form a sulfone moiety together with the ring sulphur atom to which they are attached.
  • the 3-membered heterocyclic residue contains a nitrogen atom which is substituted by one of the substituents Z 1 , Z 2 , Z 3 and Z 4 , said Z substituent represents R 11 .
  • the first Z substituent represents R 11 and the second Z substituent represents R 12 .
  • Z 1 to Z 4 represent independently of each other -CH 3 , -C2H 5 , -C3H 7 , -CH(CH 3 ) 2 , -OH, -OCH 3 , -OC 2 H 5 , -OC 3 H 7 , -NH 2 , -N(CH 3 ) 2 , -F, -CI, -Br, -I, -CN, -CH 2 F, -CHF 2 , -CF 3 , -OCHF 2 , or -OCF3.
  • R 11 represents -CH 3 , -C 2 H 5 , -C 3 H 7 , -CH(CH 3 ) 2 , -CH 2 F, -CHF 2 , -CF 3 , cyclo-C 3 H 5 , cyclo-C 4 H 7 , cyclo-C 5 H 9 , cyclo-CeHn, cyclo
  • the term "4-membered heterocyclyl” refers to a substituted or non substituted ring system of four atoms including at least one heteroatom such as O, S, SO, SO 2 , N, NO, wherein these 4-membered heterocyclic residues can be substituted with 1 to 4 substituents selected from Z 1 , Z 2 , Z 3 and Z 4 .
  • two of the substituents Z 1 , Z 2 , Z 3 and Z 4 represent together an oxygen atom and form together with the ring carbon atom of the heterocyclic ring to which they are both attached a carbonyl moiety or a sulfoxide moiety together with the ring sulphur atom to which they are attached or both Z substituents represent oxygen and form a sulfone moiety together with the ring sulphur atom to which they are attached.
  • the 4- membered heterocyclic residue contains a nitrogen atom which is substituted by one of the substituents Z 1 , Z 2 , Z 3 and Z 4 , said Z substituent represents R 11 .
  • the first Z substituent represents R 11 and the second Z substituent represents R 12 .
  • the substituent R 8 with the only difference that the optional substituents of the 4-membered heterocyclyl residue are Z 5 to Z 7 instead of Z 1 to Z 4 .
  • the optional substituent Z 1 is replaced by Z 5
  • Z 2 is replaced by Z 6
  • Z 3 is replaced by Z 7
  • Z 4 is hydrogen.
  • Z 1 to Z 4 represent independently of each other -CH 3 , -C2H 5 , -C3H 7 , -CH(CH 3 ) 2 , -OH, -OCH3, -OC2H5, -OC3H7, -NH 2 , -N(CH 3 ) 2 , -F, -CI, -Br, -I, -CN, -CH 2 F, -CHF 2 , -CF 3 , -OCHF 2 , and -OCF3.
  • Preferred substituents for R 11 are -CH 3 , -C 2 H 5 , -C 3 H 7 , -CH(CH 3 ) 2 , -CH 2 F, - -CF 3 , cyclo-C 3 H 5 , cyclo-C 4 H 7 , cyclo-C 5 H 9 , cyclo-CeHn, cyclo
  • 5-membered heterocyclyl refers to a substituted or non substituted ring system of five atoms including at least one heteroatom such as O, S, SO, SO2, N, NO, wherein these 5-mennbered heterocyclic residues can be substituted with 1 to 4 substituents selected from Z 1 , Z 2 , Z 3 and Z 4 .
  • two of the substituents Z 1 , Z 2 , Z 3 and Z 4 represent together an oxygen atom and form together with the ring carbon atom of the heterocyclic ring to which they are both attached a carbonyl moiety or a sulfoxide moiety together with the ring sulphur atom to which they are attached or both Z substituents represent oxygen and form a sulfone moiety together with the ring sulphur atom to which they are attached. If the 5-membered heterocyclic residue contains a nitrogen atom which is substituted by one of the substituents Z 1 , Z 2 , Z 3 and Z 4 , said Z substituent represents R 11 .
  • the first Z substituent represents R 11 and the second Z substituent represents R 12 .
  • the substituent R 8 with the only difference that the optional substituents of the 5-membered heterocyclyl residue are Z 5 to Z 7 instead of Z 1 to Z 4 .
  • the optional substituent Z 1 is replaced by Z 5
  • Z 2 is replaced by Z 6
  • Z 3 is replaced by Z 7
  • Z 4 is hydrogen.
  • 6-membered heterocyclyl refers to a substituted or non substituted ring system of six atoms including at least one heteroatom such as O, S, SO, SO 2 , N, NO, wherein these 6-membered heterocyclic residues can be substituted with 1 to 4 substituents selected from Z 1 , Z 2 , Z 3 and Z 4 .
  • two of the substituents Z 1 , Z 2 , Z 3 and Z 4 represent together an oxygen atom and form together with the ring carbon atom of the heterocyclic ring to which they are both attached a carbonyl moiety or a sulfoxide moiety together with the ring sulphur atom to which they are attached or both Z substituents represent oxygen and form a sulfone moiety together with the ring sulphur atom to which they are attached. If the 6-membered heterocyclic residue contains a nitrogen atom which is substituted by one of the substituents Z 1 , Z 2 , Z 3 and Z 4 , said Z substituent represents R 11 .
  • the first Z substituent represents R 11 and the second Z substituent represents R 12 .
  • the substituent R 8 with the only difference that the optional substituents of the 6-membered heterocyclyl residue are Z 5 to Z 7 instead of Z 1 to Z 4 .
  • the optional substituent Z 1 is replaced by Z 5
  • Z 2 is replaced by Z 6
  • Z 3 is replaced by Z 7
  • Z 4 is hydrogen.
  • the term "monounsaturated 4-membered heterocyclyl” refers to a substituted or non substituted ring system of four atoms including at least one heteroatom such as O, S, SO, SO 2 , N, NO, and one double bond, wherein these monounsaturated 4-membered heterocyclic residues can be substituted with 1 to 4 substituents selected from Z 1 , Z 2 , Z 3 and Z 4 .
  • can be substituted refers to the replacement of a hydrogen atom by one of the substituents Z 1 , Z 2 , Z 3 or Z 4 .
  • the monounsaturated 4- membered heterocyclic residue contains a nitrogen atom which is substituted by one of the substituents Z 1 , Z 2 , Z 3 and Z 4 , said Z substituent represents R 11 . If the monounsaturated 4-membered heterocyclic residue contains two nitrogen atoms which are both substituted by one of the substituents Z 1 , Z 2 , Z 3 and Z 4 , the first Z substituent represents R 11 and the second Z substituent represents R 12 .
  • Z 1 to Z 4 represent independently of each other -CH 3 , -C2H 5 , -C3H 7 , -CH(CH 3 ) 2 , -OH, -OCH3, -OC2H 5 , -OC3H 7 , -NH 2 , -N(CH 3 ) 2 , -F, -CI, -Br, -I, -CN, -CH 2 F, -CHF 2 , -CF 3 , -OCHF 2 , and -OCF3.
  • Preferred substituents for R 11 are -CH 3 , -C 2 H 5 , -C 3 H 7 , -CH(CH 3 ) 2 , -CH 2 F, - -CF 3 , cyclo-C 3 H 5 , cyclo-C 4 H 7 , cyclo-C 5 H 9 , cyclo-CeHn, cyclo-C 7 Hi 3;
  • the term "monounsaturated 5-membered heterocyclyl” refers to a substituted or non substituted ring system of five atoms including at least one heteroatom such as O, S, SO, SO 2 , N, NO and one double bond, wherein these monounsaturated 5-membered heterocyclic residues can be substituted with 1 to 4 substituents selected from Z 1 , Z 2 , Z 3 and Z 4 .
  • two of the substituents Z 1 , Z 2 , Z 3 and Z 4 represent together an oxygen atom and form together with the ring carbon atom of the heterocyclic ring to which they are both attached a carbonyl moiety or a sulfoxide moiety together with the ring sulphur atom to which they are attached or both Z substituents represent oxygen and form a sulfone moiety together with the ring sulphur atom to which they are attached. If the monounsaturated 5-membered heterocyclic residue contains a nitrogen atom which is substituted by one of the substituents Z 1 , Z 2 , Z 3 and Z 4 , said Z substituent represents R 11 .
  • the first Z substituent represents R 11 and the second Z substituent represents R 12 .
  • Z 1 to Z 4 represent independently of each other -CH 3 , -C2H 5 , -C3H 7 , -CH(CH 3 ) 2 , -OH, -OCH3, -OC2H5, -OC3H7, -NH 2 , -N(CH 3 ) 2 , -F, -CI, -Br, -I, -CN, -CH 2 F, -CHF 2 , -CF 3 , -OCHF 2 , and -OCF3.
  • the term "monounsaturated 6-membered heterocyclyl” refers to a substituted or non substituted ring system of six atoms including at least one heteroatom such as O, S, SO, SO 2 , N, NO, and one double bond, wherein these monounsaturated 6-membered heterocyclic residues can be substituted with 1 to 4 substituents selected from Z 1 , Z 2 , Z 3 and Z 4 .
  • two of the substituents Z 1 , Z 2 , Z 3 and Z 4 represent together an oxygen atom and form together with the ring carbon atom of the heterocyclic ring to which they are both attached a carbonyl moiety or a sulfoxide moiety together with the ring sulphur atom to which they are attached or both Z substituents represent oxygen and form a sulfone moiety together with the ring sulphur atom to which they are attached. If the monounsaturated 6-membered heterocyclic residue contains a nitrogen atom which is substituted by one of the substituents Z 1 , Z 2 , Z 3 and Z 4 , said Z substituent represents R 11 .
  • the first Z substituent represents R 11 and the second Z substituent represents R 12 .
  • Examples of preferred monounsaturated 6-membered heterocyclic groups and substituted 6-membered heterocyclic groups for R 3 are ⁇
  • Z 1 to Z 4 represent independently of each other -CH 3 , -C2H 5 , -C3H 7 , -CH(CH 3 ) 2 , -OH, -OCH 3 , -OC 2 H 5 , -OC 3 H 7 , -NH 2 , -N(CH 3 ) 2 , -F, -CI, -Br, -I, -CN, -CH 2 F, -CHF 2 , -CF 3 , -OCHF 2 , and -OCF3.
  • Preferred substituents for R 11 are -CH 3 , -C 2 H 5 , -C 3 H 7 , -CH(CH 3 ) 2 , -CH 2 F, - -CF 3 , cyclo-C 3 H 5 , cyclo-C 4 H 7 , cyclo-C 5 H 9 , cyclo-CeHn, cyclo
  • carbocyclyl refers to C 3 -C8-cycloalkyl, 3-membered carbocyclyl, 4-membered carbocyclyl, 5-membered carbocyclyl, and 6-membered carbocyclyl.
  • R 8 the optional substituents of the 4-membered carbocyclyl residue are Z 5 to Z 7 instead of Z 1 to Z 4 .
  • R 8 the optional substituent Z 1 is replaced by Z 5
  • Z 2 is replaced by Z 6
  • Z 3 is replaced by Z 7
  • Z 4 is hydrogen.
  • R 8 the optional substituents of the 5-membered carbocyclyl residue are Z 5 to Z 7 instead of Z 1 to Z 4 .
  • R 8 the optional substituent Z 1 is replaced by Z 5
  • Z 2 is replaced by Z 6
  • Z 3 is replaced by Z 7
  • Z 4 is hydrogen.
  • R 8 the optional substituents of the 6-membered carbocyclyl residue are Z 5 to Z 7 instead of Z 1 to Z 4 .
  • R 8 the optional substituent Z 1 is replaced by Z 5
  • Z 2 is replaced by Z 6
  • Z 3 is replaced by Z 7
  • Z 4 is hydrogen.
  • 6-membered aryl refers to phenyl, substituted phenyl as well as to benzo residues where a non aromatic ring is condensed to a benzo ring such as a benzodioxol:
  • the term "5-membered heteroaryl” refers to a substituted or non substituted aromatic ring system of five atoms including at least one heteroatom such as O, S, SO, SO 2 , N, NO, wherein these aromatic 5-membered heterocyclic residues can be substituted with 1 to 4 substituents selected from Z 1 , Z 2 , Z 3 and Z 4 .
  • can be substituted refers to the replacement of a hydrogen atom by one of the substituents Z 1 , Z 2 , Z 3 or Z 4 .
  • Z 1 to Z 4 represent independently of each other -CH 3 , -C2H 5 , -C3H 7 , -CH(CH 3 ) 2 , -OH, -OCH3, -OC2H5, -OC3H7, -NH 2 , -N(CH 3 ) 2 , -F, -CI, -Br, -I, -CN, -CH 2 F, -CHF 2 , -CF 3 , -OCHF 2 , and -OCF3.
  • 6-membered heteroaryl refers to a substituted or non substituted aromatic ring system of six atoms including at least one heteroatom such as O, S, SO, SO 2 , N, NO, wherein these aromatic 6-membered heterocyclic residues can be substituted with 1 to 4 substituents selected from Z 1 , Z 2 , Z 3 and Z 4 .
  • can be substituted refers to the replacement of a hydrogen atom by one of the substituents Z 1 , Z 2 , Z 3 or Z 4 .
  • 6-membered heteroaryl groups can be substituted with 1 to 4 substituents selected from Z 1 , Z 2 , Z 3 and Z 4 .
  • R 3 and R 4 are not single substituent and that R 3 together with R 4 can form a carbocydic or heterocyclic 4-, 5-, 6- or 7-membered ring with the two carbon atoms of the benzo ring to which R 3 and R 4 are attached and that 4-, 5-, 6- or 7-membered ring can be aromatic or non aromatic and can be substituted with 1 to 4 substituents selected from Z 1 , Z 2 , Z 3 and Z 4 .
  • heterocyclic 4-membered ring is used synonymic for the term “4-membered heterocyclyl”.
  • R 11 and R 12 together with the atoms to which they are attached represent a “heterocyclic 4-membered ring”
  • the optional substituents Z 1 to Z 4 are replaced by the optional substituents Z 8 to Z 13 .
  • heterocyclic 5-membered ring is used synonymic for the term “5-membered heterocyclyl”.
  • R 11 and R 12 together with the atoms to which they are attached represent a “heterocyclic 5-membered ring”
  • the optional substituents Z 1 to Z 4 are replaced by the optional substituents Z 8 to Z 15 .
  • heterocyclic 6-membered ring is used synonymic for the term “6-membered heterocyclyl”.
  • R 11 and R 12 together with the atoms to which they are attached represent a “heterocyclic 6-membered ring”
  • the optional substituents Z 1 to Z 4 are replaced by the optional substituents Z 8 to Z 15 .
  • heterocyclic 7-membered ring is used synonymic for the term “7-membered heterocyclyl”.
  • the phenyl group together with R 3 and R 4 form the following bicyclic systems which can be further substituted with 1 to 4 substituents selected from Z 1 , Z 2 , Z 3 and Z 4 on the ring formed by R 3 and R 4 as well as with R 5 , R 6 and R 7 on the phenyl group which is the benzo group in the bicyclic ring:
  • carbocyclyl refers preferably to a Cs-Ce-cycloalkyl as disclosed above. Moreover the carbocyclyl residues can be substituted with 1 to 3 substituents selected from Z 5 , Z 6 and Z 7 . Thus, the above-mentioned Cs-Cs-cycloalkyl residues are examples for carbocyclyl residues which can be substituted with one, two or three substituents selected from Z 5 , Z 6 and Z 7 . Further, it is clear to a skilled person that the term "can be substituted” refers to the replacement of a hydrogen atom by one of the substituents Z 5 , Z 6 and Z 7 .
  • carbocyclyl refers to carbocyclic residues with 3 to 8 ring carbon atoms which may also be partly unsaturated but not aromatic such as.
  • carbocyclyl refers for example to cyclohexdienyl (- ⁇ / ), but not to phenyl (-C6H 5 ).
  • Z 5 , Z 6 and Z 7 represent independently of each other -CH 3 , -C2H 5 , -C3H 7 , -CH(CH 3 ) 2 , -OH, -OCH3, -OC 2 H 5 , -OC 3 H 7 , -NH 2 , -N(CH 3 ) 2 , -F, -CI, -Br, -I, -CN, -CH 2 F, -CHF 2 , -CF 3 , -OCHF 2 , and -OCF3.
  • the term “naturebridging carbocyclyl” refers to a carbocyclyl residue as disclosed herein, which is further bonded to a second substituent independent from any optional substitution with substituents Z 1 , Z 2 , Z 3 or Z 4 .
  • a "bridging carbocycly” two hydrogen atoms are replaced by residues rendering the ..bridging carbocyclyl" a di-yl moiety.
  • the ..bridging carbocyclyl binds the two different residues with two different carbon atoms, therby preventing a substitution pattern wherein the two residues are bonded to the same carbon atom.
  • the ..bridging carbocyclyl can be substituted with 1 to 4 substituents selected from Z 1 , Z 2 , Z 3 or Z 4 .
  • the term “can be substituted” refers to the replacement of a hydrogen atom by one of the substituents Z 1 , Z 2 , Z 3 or Z 4 .
  • the term “can be substituted” refers to the replacement of a hydrogen atom by one of the substituents Z 1 , Z 2 , Z 3 or Z 4 .
  • only these hydrogen atoms which are present in the ..bridging carbocyclyl" group can be replaced by the substituents Z 1 , Z 2 , Z 3 and Z 4
  • "a bridging carbocyclyl” is attached to two different residues redering it a di-yl residue.
  • heterocyclyl refers preferably to a Ci-Cg-heterocyclyl as disclosed above. Moreover the heterocyclyl residues can be substituted with 1 to 3 substituents selected from Z 5 , Z 6 and Z 7 . Thus, the above-mentioned C1-C9- heterocyclyl residues are examples for heterocyclyl residues which can be substituted with one, two or three substituents selected from Z 5 , Z 6 and Z 7 .
  • the number of 1 to 9 carbon atoms (C1-C9) refers to the number of ring carbon atoms and does not include any carbon atoms probably present in the substituents Z 5 to Z 7 .
  • the Ci-Cg-nitrogenheterocyclyl residue is linked through the at least one nitrogen ring atom to the rest of the molecule.
  • the Ci-Cg-nitrogenheterocyclyl residue can be substituted with 1 to 3 substituents selected from Z 5 , Z 6 and Z 7 .
  • the term answering heterocyclyl refers to a heterocyclyl residue as disclosed above, which is further bonded to a second substituent independent from any optional substitution with substituents Z 1 , Z 2 , Z 3 or Z 4 .
  • a "bridging heterocycly” two hydrogen atoms are replaced by residues rendering the ..bridging heterocyclyl" a di-yl moiety.
  • the ..bridging heterocyclyl binds the two different residues with two different atoms of the heterocyclyl skeleton, therby preventing a substitution pattern wherein the two residues are bonded to the same atom.
  • the ..bridging heterocyclyl can be substituted with 1 to 4 substituents selected from Z 1 , Z 2 , Z 3 or Z 4 .
  • the term “can be substituted” refers to the replacement of a hydrogen atom by one of the substituents Z 1 , Z 2 , Z 3 or Z 4 .
  • the term “can be substituted” refers to the replacement of a hydrogen atom by one of the substituents Z 1 , Z 2 , Z 3 or Z 4 .
  • only these hydrogen atoms which are present in the ..bridging heterocyclyl" group can be replaced by the substituents Z 1 , Z 2 , Z 3 and Z 4 .
  • "a bridging heterocyclyl” is attached to two different residues redering it a di-yl residue.
  • spirocarbocyclyl refers also to the C 7 -Ci6-spiroalkyl residues as disclosed above but is not limited to these C 7 -Ci6-spiroalkyl residues. Moreover the spirocarbocyclyl residues can be substituted with 1 to 3 substituents selected from Z 5 , Z 6 and Z 7 . Thus, the above-mentioned C 7 -Ci6-spiroalkyl residues are examples for spirocarbocyclyl residues which can be substituted with one, two or three substituents selected from Z 5 , Z 6 and Z 7 .
  • the term "can be substituted” refers to the replacement of a hydrogen atom by one of the substituents Z 5 , Z 6 or Z 7 . It is also possible that two of the substituents Z 5 , Z 6 and Z 7 represent together an oxygen atom and form together with the carbon atom of the spirocarbocyclyl residue to which they are both attached a carbonyl moiety.
  • the carbon atom number of C -Ci6 refers only to the carbon atoms of the spiro residue (spiroalkyl) and does not include the carbon atoms of the substituents Z 5 to Z 7 .
  • R 8 represents preferably the following spirocarbocyclyl residues: spiro[2,3]hexyl, spiro[2,4]heptyl, spiro[2,5]octyl, spiro[2,7]nonyl, spiro[3,3]heptyl, spiro[3,4]octyl, spiro[3,5]nonyl, spiro[3,6]decyl, spiro[4,4]nonyl, spiro[4,5]decyl, spiro[4,6]undecyl, spiro[5,5]undecyl, spiro[5,6]dodecyl, spiro[6,6]tridecyl, wherein the afore-mentioned spirocarbocyclyl residues can be substituted with one to three substituents selected from Z 5 , Z 6 and Z 7
  • ..bridging spirocarbocyclyl refers to a spirocarbocyclyl residue as disclosed above, which is further bonded to a second substituent independent from any optional substitution with substituents Z 1 , Z 2 , Z 3 or Z 4 .
  • substituents Z 1 , Z 2 , Z 3 or Z 4 substituents Z 1 , Z 2 , Z 3 or Z 4 .
  • the ..bridging spirocarbocyclyl binds the two different residues with two different atoms of the spirocarbocyclyl skeleton, therby preventing a substitution pattern wherein the two residues are bonded to the same atom.
  • the ..bridging spirocarbocyclyl can be substituted with 1 to 4 substituents selected from Z 1 , Z 2 , Z 3 or Z 4 . It is clear to a skilled person that the term "can be substituted” refers to the replacement of a hydrogen atom by one of the substituents Z 1 , Z 2 , Z 3 or Z 4 .
  • the term "can be substituted” refers to the replacement of a hydrogen atom by one of the substituents Z 1 , Z 2 , Z 3 or Z 4 .
  • the term "can be substituted” refers to the replacement of a hydrogen atom by one of the substituents Z 1 , Z 2 , Z 3 or Z 4 .
  • only these hydrogen atoms which are present in the ..bridging spirocarbocyclyl" group can be replaced by the substituents Z 1 , Z 2 , Z 3 and Z 4 .
  • "a bridging spirocarbocyclyl” is attached to two different residues redering it a di-yl residue.
  • spiroheterocyclyl refers to C5-C14/N0-N2/O0-O2/S0-S1- spiroheterocyclyl residues comprising or including the Cs-Cu-spiroheterocyclyl residues as disclosed above. Moreover the C5-C14/N0-N2/O0-O2/S0-S1- spiroheterocyclyl residues or the Cs-Cu-spiroheterocyclyl residues can be substituted with 1 to 3 substituents selected from Z 5 , Z 6 and Z 7 .
  • C 5 -Ci 4 -spiroheterocyclyl residues are examples for C5-C14/N0-N2/O0- 02/So-Si-spiroheterocyclyl residues which can be substituted with one, two or three substituents selected from Z 5 , Z 6 and Z 7 .
  • the term "can be substituted" refers to the replacement of a hydrogen atom by one of the substituents Z 5 , Z 6 or Z 7 .
  • the substituents Z 5 , Z 6 and Z 7 represent together an oxygen atom and form together with the carbon atom of the spiroheterocyclyl residue to which they are both attached a carbonyl moiety.
  • the C 5 -Ci4/No-N 2 /Oo-02/So-Si-spiroheterocyclyl residues are characterized by that the spiroheterocyclyl residue is linked through a carbon atom of the spiro ring system and not through the hetero atom, i.e. the nitrogen atom of the spiro ring system. If the spiroheterocyclyl residue contains a nitrogen atom which is substituted by one of the substituents Z 5 , Z 6 and Z 7 , said Z substituent represents R 12 .
  • the first Z substituent represents R 11 and the second Z substituent
  • N 2 refers to the groups and -R 12
  • Si refers to the group -S- or
  • the indication "So” means that no sulfur is present in the spiroheterocyclyl residue.
  • the indication ⁇ refers to the group -O- and the indication ⁇ 2" to two groups -O- which are not directly linked to each other, while "Oo" indicates that no oxygen is present in the spiro ring system.
  • the C 5 -Ci4/N 0 -N 2 /Oo-02/So-Si-spiroheterocyclyl residues can contain up to two nitrogen atoms and up to two oxygen atoms and one sulfur atom while in total not more than 3 hetero atoms should be present in the spiro ring system.
  • heteroatoms in the spiro ring system are not directly bond to each other.
  • the numbers of atoms "C5-C14/N0-N2/O0-O2/S0-S1" do not include C, N, O and/or S atoms from the substituents Z 5 to Z 7 .
  • Preferred is the presence of one nitrogen atom or two nitrogen atoms or one sulfur atom or one sulfoxide moiety or one sulphone moiety or one oxygen atom or two oxygen atoms or one oxygen and one nitrogen atom in the spiro ring system.
  • the C 5 -Ci 4 -spironitrogenheterocyclyl residue is linked through the at least one nitrogen spiro cyclus atom to the rest of the molecule.
  • C 5 -Ci 4 -spironitrogenheterocyclyl residue can be substituted with 1 to 3 substituents selected from Z 5 , Z 6 and Z 7 .
  • the term answeringbridging spiroheterocyclyl refers to a spiroheterocyclyl residue as disclosed above, which is further bonded to a second substituent independent from any optional substitution with substituents Z 1 , Z 2 , Z 3 or Z 4 .
  • two hydrogen atoms are replaced by residues rendering the ..bridging spiroheterocyclyl" a di-yl moiety.
  • the ..bridging spiroheterocyclyl binds the two different residues with two different atoms of the spiroheterocyclyl skeleton, therby preventing a substitution pattern wherein the two residues are bonded to the same atom.
  • the ..bridging spiroheterocyclyl can be substituted with 1 to 4 substituents selected from Z 1 , Z 2 , Z 3 or Z 4 . It is clear to a skilled person that the term "can be substituted” refers to the replacement of a hydrogen atom by one of the substituents Z 1 , Z 2 , Z 3 or Z 4 .
  • R 8 represents preferably the following spiroheterocydyl or C 5 -Ci 4 /N 0 -N 2 /Oo-O 2 /So-Si- spiroheterocyclyl residues: spiro[2,3]heterohexyl, spiro[2,4]heteroheptyl, spiro[2,5]heterooctyl, spiro[2,7]heterononyl, spiro[3,3]heteroheptyl, spiro[3,4]heterooctyl, spiro[3,5]heterononyl, spiro[3,6]heterodecyl, spiro[4,4]heterononyl, spiro[4,5]heterodec
  • the heteroatom in the afore-mentioned spiroheterocydyl or C 5 -Ci 4 /N 0 -N 2 /Oo- O 2 /So-Si-spiroheterocyclyl residues is preferably selected from -O-, -NH-, -NR 11 -, -SO-, and -SO 2 -.
  • R represents preferably the following spiroheterocydyl or C 5 -Ci 4 /N 0 - N 2 /Oo-O 2 /So-Si-spiroheterocyclyl residues: azaspiro[3,3]heptyl, azaspiro[3,4]octyl, azaspiro[3,5]nonyl, azaspiro[3,6]decyl, azaspiro[4,4]nonyl, azaspiro[4,5]decyl, azaspiro[4,6]undecyl, azaspiro[5,5]undecyl, azaspiro[5,6]dodecyl, azaspiro[6,6]tridecyl, diazaspiro[3,3]heptyl, diazaspiro[3,4]octyl, diazaspiro[3,5]nonyl, diazaspiro
  • R 8 represents more preferably the following residues: -(CH 2 )p-NH 2 , -(CH 2 ) P - NR 16 R 17 , substituted or unsubstituted 4-membered carbocyclyl, substituted or unsubstituted 5-membered carbocyclyl, substituted or unsubstituted 6-membered carbocyclyl, 4-membered heterocyclyl, 5-membered heterocyclyl, 6-membered heterocyclyl, substituted 4-membered heterocyclyl, substituted 5-membered heterocyclyl, substituted 6-membered heterocyclyl, 4-membered nitrogenheterocyclyl, 5-membered nitrogenheterocyclyl, 6-membered nitrogenheterocyclyl, substituted 4- membered nitrogenheterocyclyl, substituted 5-membered nitrogenheterocyclyl, 6-membered nitrogenheterocyclyl, substituted 4- membered nitrogenheterocyclyl, substituted 5-membered
  • substituted oxadiazaspiro[3,5]nonyl substituted oxadiazaspiro[3,6]decyl, substituted oxadiazaspiro[4,5]decyl, substituted oxadiazaspiro[4,6]undecyl, substituted oxadiazaspiro[5,5]undecyl, substituted oxadiazaspiro[5,6]dodecyl, or substituted oxadiazaspiro[6,6]tridecyl,
  • the afore-mentioned substituted or non-substituted spiroheterocyclyl or C 5 - Ci 4 /N 0 -N 2 /Oo-O 2 /So-Si-spiroheterocyclyl residues are linked through a ring carbon atom to the rest of the molecule and wherein the afore-mentioned substituted or non- substituted spiroheterocyclyl or C 5 -Ci 4 /N 0 -N 2 /Oo-O 2 /So-Si-spiroheterocyclyl residues are optionally substituted with one to three substituents selected from Z 5 , Z 6 and Z 7 .
  • the heteroatom in the afore-mentioned substituted or non-substituted spiroheterocyclyl or C 5 -Ci 4 /N 0 -N 2 /Oo-O 2 /So-Si-spiroheterocyclyl residues is preferably selected from -O-, -NH-, -NR 11 -, -SO- and -SO 2 -.
  • Z 5 , Z 6 and Z 7 represent independently of each other -CH 3 , -C2H 5 , -C 3 H 7 , -CH(CH 3 ) 2 , -OH, -OCH 3 , -OC 2 H 5 , -OC 3 H 7 , -NH 2 , -N(CH 3 ) 2 , -F, -CI, -Br, -I, -CN, -CH 2 F, -CHF 2 , -CF 3 , -OCHF 2 , and -OCF 3 .
  • R 11 is preferably selected from: -CH 3 , -C 2 H 5 , -C 3 H 7 , -CH(CH 3 ) 2 , -CH 2 F, - -CF 3 , cyclo-C 3 H 5 , cyclo-C 4 H 7 , cyclo-C 5 H 9 , cyclo-CeHn, cyclo
  • 4-membered nitrogenheterocyclyl refers to the residue "4-membered heterocyclyl" as defined above, wherein at least one heteroatom is a nitrogen atom and the residue is linked through the at least one nitrogen ring atom to the rest of the molecule and wherein Z 1 is replaced by Z 5 , Z 2 is replaced by Z 6 , Z 3 is replaced by Z 7 , and Z 4 is hydrogen.
  • 5-membered nitrogenheterocyclyl refers to the residue "5-membered heterocyclyl" as defined above, wherein at least one heteroatom is a nitrogen atom and the residue is linked through the at least one nitrogen ring atom to the rest of the molecule and wherein Z 1 is replaced by Z 5 , Z 2 is replaced by Z 6 , Z 3 is replaced by Z 7 , and Z 4 is hydrogen.
  • 6-membered nitrogenheterocyclyl refers to the residue "6-membered heterocyclyl" as defined above, wherein at least one heteroatom is a nitrogen atom and the residue is linked through the at least one nitrogen ring atom to the rest of the molecule and wherein Z 1 is replaced by Z 5 , Z 2 is replaced by Z 6 , Z 3 is replaced by Z 7 , and Z 4 is hydrogen.
  • R represents the following residues
  • Y represents -O- -NH-, -NR - -SO- or -SO 2 -, preferably -NH- and -NR 11 - and wherein the substituents Z 5 , Z 6 and Z 7 have the meanings as defined herein.
  • spironitrogencyclyl refers to the C5-C14/N1-N3- spironitrogencyclyl residues comprising or including the Cs-Cu-spiroheterocyclyl residues as disclosed above, wherein the heteroatom is nitrogen, i.e. Y is NH or NR 1 1 .
  • C 5 -Ci 4 /Ni-N 3 means that the spiro ring system consists of 5 to 14 carbon atoms and 1 to 3 nitrogen atoms. Moreover the spironitrogencyclyl residues can be substituted with 1 to 3 substituents selected from Z 5 , Z 6 and Z 7 . However it is clear to a skilled person that the term “can be substituted” refers to the replacement of a hydrogen atom by one of the substituents Z 5 , Z 6 or Z 7 . It is also possible that two of the substituents Z 5 , Z 6 and Z 7 represent together an oxygen atom and form together with the carbon atom of the spironitrogencyclyl residue to which they are both attached a carbonyl moiety.
  • the C 5 -Ci4/Ni-N 3 -spironitrogencyclyl residues are characterized in that the spironitrogencyclyl residue is linked through a nitrogen atom of the spiro ring system and not through a carbon atom of the spiro ring system.
  • N 3 refers to a first nitrogen atom through
  • the C 5 -Ci4/Ni-N 3 -spironitrogencyclyl residue can contain one, two or three nitrogen atoms in the spiro ring system.
  • the numbers of atoms "C5-C14/N1-N2" do not include C and N atoms from the substituents Z 5 to Z 7 .
  • nitrogenheterocyclyl refers to C5-C14/N1-N3/O0-O2/S0-S1- nitrogenheterocyclyl residues comprising or including the Cs-Cu-spiroheterocyclyl residues as disclosed above, wherein the heteroatom is nitrogen, i.e. Y is NH or NR 1 1 .
  • C5-C14/N1-N3/O0-O2/S0-S1 means that the spiro ring system consists of 5 to 14 carbon atoms and 1 to 3 nitrogen atoms, 0 to 2 oxygen atoms and 0 or 1 sulfur atom.
  • the nitrogenheterocyclyl residues can be substituted with 1 to 3 substituents selected from Z 5 , Z 6 and Z 7 .
  • the term "can be substituted” refers to the replacement of a hydrogen atom by one of the substituents Z 5 , Z 6 or Z 7 . It is also possible that two of the substituents Z 5 , Z 6 and Z 7 represent together an oxygen atom and form together with the carbon atom of the nitrogenheterocyclyl residue to which they are both attached a carbonyl moiety.
  • the C 5 -Ci4/Ni-N 3 /Oo-0 2 /So-Si-nitrogenheterocyclyl residues are characterized by that the nitrogenheterocyclyl residue is linked through a nitrogen atom of the spiro ring system and not through a carbon atom of the spiro ring system.
  • nitrogenheterocyclyl residue is linked and to the group of the spiro ring system. If the nitrogenheterocyclyl residue contains a third nitrogen atom and both nitrogen atoms are substituted by one of the substituents Z 5 , Z 6 and Z 7 , the first Z substituent on the second nitrogen atom represents R 12 and the second Z substituent on the third nitrogen atom represents R 11 .
  • the indication "N 3 " refers to a first nitrogen atom through which the nitrogenheterocyclyl residue is linked and to the
  • the indication “Si” refers to the group -S- or -SO- or -SO2- of the spiro ring system.
  • the indication “So” means that no sulfur is present in the nitrogenheterocyclyl residue.
  • the C 5 -Ci4/Ni-N 3 /Oo-0 2 /So-Si-nitrogenheterocyclyl residue can contain in total 6 hetero atoms while in total not more than 3 hetero atoms should be present in the spiro ring system. Moreover it is preferred that the heteroatoms in the spiro ring system are not directly bond to each other.
  • C5-C14/N1-N3/O0-O2/S0-S1 do not include C, O, S and N atoms from the substituents
  • Preferred is the presence of one nitrogen atom or two nitrogen atoms or one nitrogen atom and one sulfur atom or one nitrogen atom and one sulfoxide moiety or one nitrogen atom and one sulphone moiety or one nitrogen atom and one oxygen atom or one nitrogen atom and two oxygen atoms or one oxygen atom and two nitrogen atoms in the spiro ring system.
  • R 9 represents preferably the following spironitrogencyclyl, nitrogenheterocyclyl, C 5 -Ci4/Ni-N 3 -spironitrogencyclyl or C5-C14/N1-N3/O0-O2/S0-S1- nitrogenheterocyclyl residues: 4-membered nitrogenheterocyclyl, 5-membered nitrogenheterocyclyl, 6-membered nitrogenheterocyclyl, 5-membered dinitrogenheterocyclyl, 6-membered dinitrogenheterocyclyl, spiro[2,3]heterohexyl, spiro[2,4]heteroheptyl, spiro[2,5]heterooctyl, spiro[2,7]heterononyl, spiro[3,3]heteroheptyl, spiro[3,4]heterooctyl, spiro[3,5]heteronon
  • 5-membered dinitrogenheterocyclyl refers to the residue "5-membered heterocyclyl" as defined above, wherein two heteroatoms are nitrogen atoms and the residue is linked through a nitrogen ring atom to the rest of the molecule and wherein Z 1 is replaced by Z 5 , Z 2 is replaced by Z 6 , Z 3 is replaced by Z 7 , and Z 4 is hydrogen.
  • 6-membered dinitrogenheterocyclyl refers to the residue "6-membered heterocyclyl" as defined above, wherein two heteroatoms are nitrogen atoms and the residue is linked through a nitrogen ring atom to the rest of the molecule and wherein Z 1 is replaced by Z 5 , Z 2 is replaced by Z 6 , Z 3 is replaced by Z 7 , and Z 4 is hydrogen.
  • the afore-mentioned spironitrogencyclyl, nitrogenheterocyclyl, C 5 -Ci 4 /Ni-N 3 - spironitrogencyclyl or C 5 -Ci 4 /Ni-N 3 /Oo-O2/So-Si-nitrogenheterocyclyl residues contain at least one nitrogen atom through which these residues are linked to the rest of the molecule and may contain one or two further moieties selected from oxygen (- O-), sulfoxide (-SO-), sulfone (-SO 2 -), carbonyl (-CO-) and nitrogen (-NR 1 1 -).
  • Preferable substituents Z 5 , Z 6 and Z 7 represent independently of each other -CH 3 , -C 2 H 5 , -C 3 H 7 , -CH(CH 3 ) 2 , -OH, -OCH 3 , -OC 2 H 5 , -OC 3 H 7 , -NH 2 , -NHCH 3 , -N(CH 3 ) 2 , -F, -CI, -Br, -I, -CN, -CH 2 F, -CHF 2 , -CF 3 , -OCHF 2 , and -OCF 3 .
  • R 11 and R 12 are preferably selected from: -CH 3 , -C 2 H 5 , -C 3 H 7 , - 2 , -CH 2 F, -CHF 2 , -CF 3 , cyclo-C 3 H 5 , cyclo-C 4 H 7 , cyclo-C 5 H 9 , cyclo-CeHn, cyclo
  • R 9 represents the following spironitrogencyclyl, nitrogenheterocyclyl, C 5 -Ci 4 /Ni-N 3 -spironitrogencyclyl or C 5 -Ci 4 /Ni-N 3 /Oo-O 2 /So-Si-nitrogenheterocyclyl residues: 4-membered nitrogenheterocyclyl linked through the nitrogen atom to the rest of the molecule, 5-membered nitrogenheterocyclyl linked through the nitrogen atom to the rest of the molecule, 6-membered nitrogenheterocyclyl linked through the nitrogen atom, substituted 4-membered nitrogenheterocyclyl linked through the nitrogen atom, substituted 5-membered nitrogenheterocyclyl linked through the nitrogen atom, substituted 6-membered nitrogenheterocyclyl linked through the nitrogen atom, 5-membered dinitrogenheterocyclyl linked through a nitrogen atom, 6- membered dinitrogenheterocyclyl linked through
  • R 9 represents the following spironitrogencyclyl, nitrogenheterocyclyl, C 5 -Ci 4 /Ni-N 3 -spironitrogencyclyl or C 5 -Ci 4 /Ni-N 3 /Oo-O 2 /So-Si- nitrogenheterocyclyl residues: azaspiro[3,3]heptyl linked through the nitrogen atom, azaspiro[3,4]octyl linked through the nitrogen atom, azaspiro[3,5]nonyl linked through the nitrogen atom, azaspiro[3,6]decyl linked through the nitrogen atom, azaspiro[4,4]nonyl linked through the nitrogen atom, azaspiro[4,5]decyl linked through the nitrogen atom, azaspiro[4,6]undecyl linked through the nitrogen atom, azaspiro[5,5]undecyl linked through the nitrogen atom, azaspiro[
  • diazaspiro[3,3]heptyl linked through a nitrogen atom diazaspiro[3,4]octyl linked through a nitrogen atom, diazaspiro[3,5]nonyl linked through a nitrogen atom, diazaspiro[3,6]decyl linked through a nitrogen atom, diazaspiro[4,4]nonyl linked through a nitrogen atom, diazaspiro[4,5]decyl linked through a nitrogen atom, diazaspiro[4,6]undecyl linked through a nitrogen atom, diazaspiro[5,5]undecyl linked through a nitrogen atom, diazaspiro[5,6]dodecyl linked through a nitrogen atom, diazaspiro[6,6]tridecyl linked through a nitrogen atom,
  • substituted diazaspiro[3,3]heptyl linked through a nitrogen atom substituted diazaspiro[3,4]octyl linked through a nitrogen atom, substituted diazaspiro[3,5]nonyl linked through a nitrogen atom, substituted diazaspiro[3,6]decyl linked through a nitrogen atom, substituted diazaspiro[4,4]nonyl linked through a nitrogen atom, substituted diazaspiro[4,5]decyl linked through a nitrogen atom, substituted diazaspiro[4,6]undecyl linked through a nitrogen atom, substituted diazaspiro[5,5]undecyl linked through a nitrogen atom, substituted diazaspiro[5,6]dodecyl linked through a nitrogen atom, substituted diazaspiro[6,6]tridecyl linked through a nitrogen atom,
  • triazaspiro[3,5]nonyl linked through a nitrogen atom triazaspiro[3,6]decyl linked through a nitrogen atom, triazaspiro[4,5]decyl linked through a nitrogen atom, triazaspiro[4,6]undecyl linked through a nitrogen atom, triazaspiro[5,5]undecyl linked through a nitrogen atom, triazaspiro[5,6]dodecyl linked through a nitrogen atom, triazaspiro[6,6]tridecyl linked through a nitrogen atom, substituted triazaspiro[3,5]nonyl linked through a nitrogen atom, substituted triazaspiro[3,6]decyl linked through a nitrogen atom, substituted triazaspiro[4,5]decyl linked through a nitrogen atom, substituted triazaspiro[4,6]undecyl linked through a nitrogen atom, substituted triazaspiro[5,5]und
  • substituted oxazaspiro[3,3]heptyl linked through a nitrogen atom substituted oxazaspiro[3,4]octyl linked through a nitrogen atom, substituted oxazaspiro[3,5]nonyl linked through a nitrogen atom, substituted oxazaspiro[3,6]decyl linked through a nitrogen atom, substituted oxazaspiro[4,4]nonyl linked through a nitrogen atom, substituted oxazaspiro[4,5]decyl linked through a nitrogen atom, substituted oxazaspiro[4,6]undecyl linked through a nitrogen atom, substituted oxazaspiro[5,5]undecyl linked through a nitrogen atom, substituted oxazaspiro[5,6]dodecyl linked through a nitrogen atom, substituted oxazaspiro[6,6]tridecyl linked through a nitrogen atom,
  • substituted oxadiazaspiro[3,5]nonyl linked through a nitrogen atom substituted oxadiazaspiro[3,6]decyl linked through a nitrogen atom, substituted oxadiazaspiro[4,5]decyl linked through a nitrogen atom, substituted oxadiazaspiro[4,6]undecyl linked through a nitrogen atom, substituted oxadiazaspiro[5,5]undecyl linked through a nitrogen atom, substituted oxadiazaspiro[5,6]dodecyl linked through a nitrogen atom, substituted oxadiazaspiro[6,6]tridecyl linked through a nitrogen atom, wherein the afore-mentioned substituted spironitrogencyclyl, substituted nitrogenheterocyclyl, substituted C 5 -Ci 4 /Ni- N 3 -spironitrogencyclyl or substituted C 5 -Ci
  • substituted or non-substituted spironitrogencyclyl, substituted or non-substituted nitrogenheterocyclyl, substituted or non-substituted C 5 - Ci 4 /Ni-N 3 -spironitrogencyclyl or substituted or non-substituted C 5 -Ci 4 /Ni-N 3 /Oo- 0 2 /So-Si-nitrogenheterocyclyl residues contain at least one nitrogen atom through which these residues are linked through the rest of the molecule and may contain one or two further moieties selected from oxygen (-O-), sulfoxide (-SO-), sulfone (-SO 2 -), carbonyl (-CO-) and nitrogen (-NR 12 -).
  • R 9 represents the following spironitrogencyclyl, nitrogenheterocyclyl, C 5 -Ci 4 /Ni-N 3 -spironitrogencyclyl or C 5 -Ci 4 /Ni-N 3 /Oo-O 2 /So-Si- nitrogenheterocyclyl residues:
  • Y represents -O-, -NH-, -NR 1 1 -, -SO- or -SO2-, preferably -NH- and -NR 1 1 - and wherein the substituents Z 5 , Z 6 and Z 7 have the meanings as defined herein.
  • Z 5 , Z 6 and Z 7 represent independently of each other -CH 3 , -C2H 5 , -C 3 H 7 , -CH(CH 3 ) 2 , -OH, -OCH 3 , -OC 2 H 5 , -OC 3 H 7 , -NH 2 , -NH(CH 3 ), -N(CH 3 ) 2 , -F, -CI, -Br, -I, -CN, -CH 2 F, -CHF 2 , -CF 3 , -OCHF 2 , and -OCF 3 , more preferably -NH 2 , -NH(CH 3 ), -N(CH 3 ) 2 .
  • R 1 1 and R 12 is preferably selected from: -CH 3 , -C 2 H 5 , -C 3 H 7 , -CH(CH 3 ) 2 , -CH 2 F, -CHF 2 , -CF 3 , cyclo-C 3 H 5 , cyclo-C 4 H 7 , cyclo-C 5 H 9 , cyclo-CeHn , cyclo-C 7 Hi 3 ,
  • novel compounds according to the general formula (I) represent chiral compounds.
  • the novel compounds according to the general formula (I) represent a racemate, or a S or a R enantiomer or a mixture of isomers.
  • the compound according to the general formula (I) is selected from the group of compounds depicted in the following Table 1 .
  • the compounds of the present invention may form salts with organic or inorganic acids or bases.
  • suitable acids for such acid addition salt formation are hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, acetic acid, citric acid, oxalic acid, malonic acid, salicylic acid, p-aminosalicylic acid, malic acid, fumaric acid, succinic acid, ascorbic acid, maleic acid, sulfonic acid, phosphonic acid, perchloric acid, nitric acid, formic acid, propionic acid, gluconic acid, lactic acid, tartaric acid, hydroxymaleic acid, pyruvic acid, phenylacetic acid, benzoic acid, p-aminobenzoic acid, p-hydroxybenzoic acid, methanesulfonic acid, ethanesulfonic acid, nitrous acid, hydroxyethanesulfonic acid, ethylenesulfonic acid, p-toluenesul
  • salts could also be formed with inorganic or organic bases.
  • suitable inorganic or organic bases are, for example, NaOH, KOH, NH OH, tetraalkylammonium hydroxide, lysine or arginine and the like.
  • Salts may be prepared in a conventional manner using methods well known in the art, for example by treatment of a solution of the compound of the general formula (I) with a solution of an acid, selected out of the group mentioned above.
  • inventive pyrazolo[1 ,5-a][1 ,3,5]triazines according to the present invention can be prepared by methods known to one skilled in the art.
  • the synthesis is preferably carried out according to the general synthetic sequences, shown in schemes 3 and 4. This enables those skilled in the art to introduce to intermediate (IV) any suitable amine R 2 - NH 2 that is commercially available or can be synthesized according to or in analogy to literature procedures.
  • intermediate (IV) any suitable amine R 2 - NH 2 that is commercially available or can be synthesized according to or in analogy to literature procedures.
  • a methylsulfoxide leaving group by oxidation of the thioatom in (V) compounds with this formed methylsulfoxide group provides the basis to react with many classes of C-, S-, N- or O-nucleophiles that are available either commercially or by synthetic means.
  • the residue A 1 can be introduced by nuclephilic substitution reaction of (IV) with amines of the formula A 1 NH 2 , and DIPEA as a base yielding 4-amino-2- (methylthio)pyrazolo[1 ,5-a][1 ,3,5]triazines (V) as shown in scheme 3, wherein A 1 represents the upper benzyl building block of the compounds of the general formula (I)
  • Suitable protection groups are, for example, substituents such as alkyl sulfonyl e.g. tert. -butyl sulfonyl, alkyl silyl e.g. trimethyl silyl, alkyl, hydroxy, alcoholates, alkyl sulfinyl such as tert. -butyl sulfinyl and hydroyxalkyi such as 2-hydroxy-1 -isopropylethyl.
  • substituents such as alkyl sulfonyl e.g. tert. -butyl sulfonyl, alkyl silyl e.g. trimethyl silyl, alkyl, hydroxy, alcoholates, alkyl sulfinyl such as tert. -butyl sulfinyl and hydroyxalkyi such as 2-hydroxy-1 -isopropylethyl.
  • PG represents a suitable imine protection group such as alkyl sulfonyl e.g. tert. -butyl sulfonyl, alkyl silyl e.g. trimethyl silyl, alkyl, hydroxyl, alcoholates, alkyl sulfinyl such as tert.-butyl sulfinyl and hydroyxalkyl such as 2-hydroxy-1 -isopropylethyl, and R 1 , R 3 to R 7 are as defined herein.
  • alkyl sulfonyl e.g. tert. -butyl sulfonyl
  • alkyl silyl e.g. trimethyl silyl
  • alkyl sulfinyl such as tert.-butyl sulfinyl and hydroyxalkyl such as 2-hydroxy-1 -isopropylethyl
  • alpha-substituent R 1 in compounds of the general formula (I) is different from hydrogen, and preferably represents -CH 3 , which can easily be introduced by any amine of the formula A 1 -NH 2 .
  • substitution pattern at the phenyl group in the form of the substitients R 3 -R 7 the skilled person will recognize that this can also be addressed readily by amines of the formula A 1 -NH 2 .
  • Starting from a wide range of commercially available materials many synthetic approaches can therefore conveniently be applied to introduce these moieties at the respective position to yield compounds as defined in claim 1 and are well known to a person skilled in the art of synthesis. This can explicitly be performed by following any of the synthetic approaches as outlined above in schemes 3 and 4, where the moiety A1 -NH 2 can be conveniently introduced at different stages of the respective synthetic routes.
  • intermediate (VI) can be reacted with different nucleophiles to give derivatives (VII)-(IX) that all bear different residues A 2 to A 7 at the afore-mentioned R 2 position in (I) in scheme 3.
  • amides of formula (XII) were synthesized via introduction of a cyanide group, transforming the resulting nitriles into imidoesters (XI) which underwent a subsequent nucleophilic attack with primary or secondary amines A 3 A 4 NH and hydrolysis to yield said related amides (scheme 7).
  • the residue R 2 is represented by the amide group - CO-NA 3 A 4 .
  • R 2 -CO-NH-(CH 2 )n-NH 2
  • R 2 -CO-NR 10 -(CH 2 ) n -R 9
  • a 3 R 10 and A 4 represents (CH 2 ) n -R 9 .
  • a 5 can be selected from the group consisting of -R 8 , -(CH 2 ) n -R 8 , -(CH 2 ) n -R 9 , -R 9 , -(CH 2 )c-(G 1 )d-(CH2)e-(G 2 )f-(CH2) g -R 8 and -(CH 2 )c-(G 1 )d-(CH2)e-(G 2 )f-CH 2 -R 9 , wherein G, c, d, e, f, g, n, R 8 and R 9 are as defined herein for the respective examples of R 2 as specified above for scheme 7.
  • a 2 can be selected from the group consisting of -R 8 , -(CH 2 ) n -R 8 , -(CH 2 ) n -R 9 , -(CH2)c-(G 1 )d-(CH2)e-(G 2 )f-(CH 2 )g-R 8 and -(CH 2 )c-(G 1 )d-(CH2)e-(G 2 )f-CH 2 -R 9 , wherein G, c, d, e, f, g, n, R 8 and R 9 are as defined herein for the respective examples of R 2 as specified above for scheme 8.
  • R 2 being -(CH 2 ) m -NH-(CH 2 ) n -R 9
  • m 0 and then A 6 represents H and A 7 is selected from the group consisting of -(CH 2 ) n -R 9 , wherein R 9 is as defined herein.
  • R 2 being -(CH 2 )m-NR 10 -(CH 2 )n-R 9
  • m 0 and then A 6 represents R 10 and A 7 is selected from the group consisting of -(CH 2 ) n -R 9 , wherein R 9 and R 10 are as defined herein.
  • R 2 being -(CH2)a-(Q)b-(CH2)c-(G 1 )d-(CH2)e-(G 2 )f-(CH2)g-R 8
  • R 2 being -(CH2)a-(Q)b-(CH2)c-(G 1 )d-(CH2)e-(G 2 )f-CH2-R 9
  • a nitro group can be reduced to an amino group, such an amino group can be converted to a sulfonamide by reaction with a sulfonyl chloride, to a carboxamide by reaction with a carbonyl chloride or another activated derivative of a carboxylic acid, to an urea by reaction with an isocyanate.
  • Carbamate substituents may be cleaved to amino groups, in particular terf-butyl carbamates by reaction with acids like trifluoroacetic acid or hydrochloric acid.
  • Formyl groups may be converted to aminomethyl groups by reaction with primary amines under conditions of a reductive amination.
  • novel compounds according to the general formula (I) are used as pharmaceutically active agent.
  • Further aspects of the present invention relate to the use of the compounds of general formula (I) for the preparation of a pharmaceutical composition useful for prophylaxis and/or treatment of infectious diseases including opportunistic diseases, immunological diseases, autoimmune diseases, cardiovascular diseases, cell proliferative diseases, inflammation, erectile dysfunction and stroke.
  • the compounds according to the general formula (I) are for the preparation of a pharmaceutical composition for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases and opportunistic infections.
  • infectious diseases comprises infections caused by viruses, bacteria, prions, fungi, and/or parasites.
  • virally induced infectious diseases including opportunistic diseases
  • the virally induced infectious diseases are caused by retroviruses, human endogenous retroviruses (HERVs), hepadnaviruses, herpesviruses, flaviviridae, and/or adenoviruses.
  • HERVs human endogenous retroviruses
  • hepadnaviruses hepadnaviruses
  • herpesviruses herpesviruses
  • flaviviridae flaviviridae
  • adenoviruses adenoviruses
  • the retroviruses are selected from lentiviruses or oncoretroviruses, wherein the lentivirus is preferably selected from the group comprising: HIV-1 , HIV-2, feline immunodeficiency virus (FIV), bovine immunodeficiency virus (BIV), sivian immunodeficiency viruses (SIVs), chimeras of HIV and SIV (SHIV), caprine arthritis encephalitis virus (CAEV), visna/maedi virus (VMV) or equine infectious anemia virus (EIAV), preferably HIV-1 and HIV-2, and the oncoretrovirus is preferably selected from HTLV-I, HTLV-II or bovine leukemia virus (BLV), preferably HTLV-I and HTLV-II.
  • the lentivirus is preferably selected from the group comprising: HIV-1 , HIV-2, feline immunodeficiency virus (FIV), bovine immunodeficiency virus (BIV), sivian immunodeficiency viruses (SIV
  • the hepadnavirus is preferably selected from HBV, ground squirrel hepatitis virus (GSHV) or woodchuck hepatitis virus (WHV), preferably HBV
  • the herpesvirus is selected from the group comprising: Herpes simplex virus I (HSV I), herpes simplex virus II (HSV II), Epstein-Barr virus (EBV), varicella zoster virus (VZV), human cytomegalovirus (HCMV) or human herpesvirus 8 (HHV-8), preferably HCMV
  • the flaviviridae is selected from HCV, West nile or Yellow Fever.
  • viruses mentioned above also comprise drug resistant virus strains.
  • infectious diseases are AIDS, Alveolar Hydatid Disease (AHD, Echinococcosis), Amebiasis (Entamoeba histolytica Infection), Angiostrongylus Infection, Anisakiasis, Anthrax, Babesiosis (Babesia Infection), Balantidium Infection (Balantidiasis), Baylisascaris Infection (Raccoon Roundworm), Bilharzia (Schistosomiasis), Blastocystis hominis Infection (Blastomycosis), Boreliosis, Botulism, Brainerd Diarrhea, Brucellosis, BSE (Bovine Spongiform Encephalopathy), Candidiasis, Capillariasis (Capillaria Infection), CFS (Chronic Fatigue Syndrome), Chagas Disease (American Trypanosomiasis), Chickenpox (Varicella-Zoster virus), Chlamydia pneumoniae Infection, Cholera
  • Another aspect of the present invention is directed to the use of at least one compound of the general formula (I) and/or pharmaceutically acceptable salts thereof for prophylaxis and/or treatment of immunological diseases, neuroimmunological diseases, and autoimmune diseases.
  • Immunological diseases are, for instance, asthma and diabetes, rheumatic and autoimmune diseases, AIDS, rejection of transplanted organs and tissues (cf. below), rhinitis, chronic obstructive pulmonary diseases, osteoporisis, ulcerative colitis, sinusitis, lupus erythematosus, recurrent infections, atopic dermatitis / eczema and occupational allergies, food allergies, drug allergies, severe anaphylactic reactions, anaphylaxis, and other manifestations of allergic disease, as well as uncommon problems such as primary immunodeficiencies, including antibody deficiency states, cell mediated immunodeficiencies (e.g., severe combined immunodeficiency, DiGeorge syndrome, Hyper-lgE syndrome, Wiskott-Aldrich syndrome, ataxia- telangiectasia), immune mediated cancers, and white cell defects.
  • primary immunodeficiencies including antibody deficiency states, cell mediated immunodeficiencies (e.g.,
  • autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis (RA), multiple sclerosis (MS), immune-mediated or type 1 diabetes mellitus, immune mediated glomerulonephritis, scleroderma, pernicious anemia, alopecia, pemphigus, pemphigus vulgaris, myasthenia gravis, inflammatory bowel diseases, Crohn's disease, psoriasis, autoimmune thyroid diseases, and Hashimoto's disease, dermatomyositis, goodpastture syndrome, myasthenia gravis pseudoparalytica, ophtalmia sympatica, phakogene uveitis, chronical agressivce hepatitis, primary billiary cirrhosis, autoimunehemolytic anemy, Werlof disease, specific cells uncontrollably attack the body's own tissues and organs (autoimmunity), producing inflammatory reactions and other serious symptoms and
  • Hashimoto's thyroiditis is one of the most common autoimmune diseases. "Autoimmune disease” refers to a category of more than 80 chronic illnesses, that can affect everything from the endocrine glands (like the thyroid) to organs like the kidneys, as well as to the digestive system.
  • autoimmune diseases There are many different autoimmune diseases, and they can each affect the body in different ways.
  • the autoimmune reaction is directed against the brain in multiple sclerosis and the gut in Crohn's disease.
  • autoimmune diseases such as systemic lupus erythematosus (lupus)
  • affected tissues and organs may vary among individuals with the same disease.
  • One person with lupus may have affected skin and joints whereas another may have affected skin, kidney, and lungs.
  • damage to certain tissues by the immune system may be permanent, as with destruction of insulin-producing cells of the pancreas in type 1 diabetes mellitus.
  • inventive compounds are also useful for prophylaxis and/or treatment of cardiovascular diseases such as cardiac hypertrophy, adult congenital heart disease, aneurysm, stable angina, unstable angina, angina pectoris, angioneurotic edema, aortic valve stenosis, aortic aneurysm, arrhythmia, arrhythmogenic right ventricular dysplasia, arteriosclerosis, arteriovenous malformations, atrial fibrillation, Behcet syndrome, bradycardia, cardiac tamponade, cardiomegaly, congestive cardiomyopathy, hypertrophic cardiomyopathy, restrictive cardiomyopathy, cardiovascular disease prevention, carotid stenosis, cerebral hemorrhage, Churg-Strauss syndrome, diabetes, Ebstein's Anomaly, Eisenmenger complex, cholesterol embolism, bacterial endocarditis, fibromuscular dysplasia, congenital heart defects, heart diseases, congestive heart failure, heart valve diseases, heart attack, epid
  • cardiac hypertrophy adult congenital heart disease, aneurysms, angina, angina pectoris, arrhythmias, cardiovascular disease prevention, cardiomyopathies, congestive heart failure, myocardial infarction, pulmonary hypertension, hypertrophic growth, restenosis, stenosis, thrombosis and arteriosclerosis.
  • proliferative diseases refers also to tumors, cancer, malignancies and their metastases. Additionally it refers also to benign proliferative diseases, which may be harmful producing a "mass effect” (compression of vital organs or closure of hollow organs such as blood vessels), or benign tumors of endocrine tissues, which may overproduce certain hormones.
  • the proliferation disorders and cancers are preferably selected from the group comprising or consisting of adenocarcinoma, choroidal melanoma, acute leukemia, acoustic neurinoma, ampullary carcinoma, anal carcinoma, astrocytoma, basal cell carcinoma, pancreatic cancer, desmoid tumor, bladder cancer, bronchial carcinoma, estrogen dependent and independent breast cancer, Burkitt's lymphoma, corpus cancer, CUP-syndrome (carcinoma of unknown primary), colorectal cancer, small intestine cancer, small intestinal tumors, ovarian cancer, endometrial carcinoma, ependymoma, epithelial cancer types, Ewing's tumors, gastrointestinal tumors, gastric cancer, gallbladder cancer, gall bladder carcinomas, uterine cancer, cervical cancer, cervix, glioblastomas, gynecologic tumors, ear, nose and throat tumors, hematologic neoplasia
  • the cell proliferative disease is cancer.
  • Leukemias including but not limited to chronic lymphocytic leukemia, chronic myelogenous leukemia, acute lymphoblastic leukemia, acute myeloid leukemia, mixed lineage leukemia, bladder cancer, breast cancer, breast carcinoma, cancer of the central nervous system, colon carcinoma, gastric cancer, lung cancer, kidney cancer, melanoma, head and neck tumors (tumors of the ear, nose and throat area), ovarian cancer, ovarial carcinoma, cervical cancer, cervix, cervical carcinoma, glioblastomas, pancreatic cancer, pancreatic carcinoma, prostate cancer, stomach cancer, skin cancer, skin testis cancer, Hodgkin ' s lymphoma, liver cancer, liver metastases and renal cell carcinomas.
  • said inflammation is mediated preferably by the cytokines TNF-a, IL-1 ⁇ , GM-CSF, IL-6 and/or IL-8.
  • the compounds according to general formula (I) are pharmaceutically active agents for prophylaxis and/or treatment of inflammatory diseases.
  • these compounds are used for the manufacture of a pharmaceutical formulation for prophylaxis and/or treatment of inflammations and inflammatory diseases in mammals, including humans.
  • Inflammatory diseases can emanate from infectious and non-infectious inflammatory conditions which may result from infection by an invading organism or from irritative, traumatic, metabolic, allergic, autoimmune, or idiopathic causes as shown in the following list.
  • Acute infections can emanate from infectious and non-infectious inflammatory conditions which may result from infection by an invading organism or from irritative, traumatic, metabolic, allergic, autoimmune, or idiopathic causes as shown in the following list. Acute infections
  • the compounds disclosed herein can be used for prophylaxis and/or treatment of inflammations caused by invading organisms such as viruses, bacteria, prions, and parasites as well as for prophylaxis and/or treatment of inflammations caused by irritative, traumatic, metabolic, allergic, autoimmune, or idiopathic reasons.
  • the disclosed compounds are useful for prophylaxis and/or treatment of inflammatory diseases which are initiated or caused by viruses, parasites, and bacteria which are connected to or involved in inflammations.
  • the following bacteria are known to cause inflammatory diseases: mycoplasma pulmonis (causes e.g. chronic lung diseases (CLD), murine chronic respiratory disease), ureaplasma urealyticum (causes pneumonia in newborns), mycoplasma pneumoniae and chlamydia pneumoniae (cause chronic asthma), C. pneumoniae (causes atherosclerosis, pharyngitis to pneumonia with empyema, human coronary heart disease), Helicobacter pylori (human coronary heart disease, stomach ulcers).
  • CLD chronic lung diseases
  • murine chronic respiratory disease ureaplasma urealyticum
  • ureaplasma urealyticum causes pneumonia in newborns
  • mycoplasma pneumoniae and chlamydia pneumoniae cause chronic asthma
  • C. pneumoniae causes
  • the following viruses are known to cause inflammatory diseases: herpesviruses especially cytomegalovirus (causes human coronary heart disease).
  • the compounds disclosed herein are useful for prophylaxis and/or treatment of inflammatory diseases caused and/or induced and/or initiated and/or enhanced by the afore-mentioned bacteria or viruses.
  • the compounds of formula (I) are useful for prophylaxis and/or treatment of inflammatory diseases of the central nervous system (CNS), inflammatory rheumatic diseases, inflammatory diseases of blood vessels, inflammatory diseases of the middle ear, inflammatory bowel diseases, inflammatory diseases of the skin, inflammatory disease uveitis, inflammatory diseases of the larynx.
  • inflammatory diseases of the central nervous system are algal disorders, protothecosis, bacterial disorders, abscessation, bacterial meningitis, idiopathic inflammatory disorders, eosinophilic meningoencephalitis, feline polioencephalomyelitis, granulomatous meningoencephalomyelitis, meningitis, steroid responsive meningitis-arteritis, miscellaneous meningitis / meningoencephalitis, meningoencephalitis in greyhounds, necrotizing encephalitis, pyogranulomatous meningoencephalomyelitis, shaker dog disease, mycotic diseases of the CNS, parasitic encephalomyelitis, prion protein induced diseases, feline spongiform encephalopathy, protozoal encephalitis-encephalomyelitis, toxoplasmosis, neosporosis, sarcocystosis, encephalit
  • inflammatory rheumatic diseases are rheumatoid arthritis, scleroderma, lupus, polymyositis, dermatomyositis, psoriatic arthritis, ankylosing spondylitis, Reiters's syndrome, juvenile rheumatoid arthritis, bursitis, tendinitis (tendonitis), and fibromyositis.
  • vasculitis examples for inflammatory diseases of blood vessels are vasculitis, autoantibodies in vasculitis, microscopic polyangiitis, giant cell arteritis, Takayasu's arteritis, vasculitis of the central nervous system, thromboangiitis obliterans (Buerger's Disease), vasculitis secondary to bacterial, fungal, and parasitic infection, vasculitis and rheumatoid arthritis, vasculitis in systemic lupus erythematosus, vasculitis in the idiopathic inflammatory myopathies, relapsing polychondritis, systemic vasculitis in sarcoidosis, vasculitis and malignancy, and drug-induced vasculitis.
  • vasculitis examples for inflammatory diseases of blood vessels are vasculitis, autoantibodies in vasculitis, microscopic polyangiitis, giant cell arteritis, Takayasu's arteritis
  • inflammatory diseases of the middle ear are acute suppurative otitis media, bullous myringitis, granular myringitis, and chronic suppurative otitis media, which can manifest as mucosal disease, cholesteatoma, or both.
  • Examples for inflammatory bowel diseases are ulcerative colitis, Crohn's disease.
  • Examples for inflammatory diseases of the skin are acute inflammatory dermatoses, urticaria (hives), spongiotic dermatitis, allergic contact dermatitis, irritant contact dermatitis, atopic dermatitis, erythemal multiforme (EM minor), Stevens-Johnson syndrome (SJS, EM major), toxic epidermal necrolysis (TEN), chronic inflammatory dermatoses, psoriasis, lichen planus, discoid lupus erythematosus, and acne vulgaris.
  • Uveitis are inflammations located in and/or on the eye and may be associated with inflammation elsewhere in the body. In most circumstances, patients who have uveitis as part of a disease elsewhere in the body are aware of that illness. The majority of patients with uveitis do not have an apparent associated systemic illness. Causes of uveitis can be infectious causes, masquerade syndromes, suspected immune- mediated diseases, and/or syndromes confined primarily to the eye.
  • viruses are associated with inflammations: human immunodeficiency virus-l, herpes simplex virus, herpes zoster virus, and cytomegalovirus.
  • Bacterial or spirochetal caused, induced, initiated and/or enhanced inflammations are tuberculosis, leprosy, proprionobacterium, syphilis, Whipple's disease, leptospirosis, brucellosis, and lyme disease.
  • Parasitic (protozoan or helminthic) caused, induced, initiated and/or enhanced inflammations are toxoplasmosis, acanthameba, toxocariasis, cysticercosis, onchocerciasis.
  • inflammatory diseases caused, induced, initiated and/or enhanced by fungi are histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, sporotrichosis, blastomycosis, and cryptococcosis.
  • Masquerade syndromes are, for instance, leukemia, lymphoma, retinitis pigmentosa, and retinoblastoma.
  • Suspected immune-mediated diseases can be selected from the group comprising ankylosing spondylitis, Behcet's disease, Crohn's disease, drug or hypersensitivity reaction, interstitial nephritis, juvenile rheumatoid arthritis, Kawasaki's disease, multiple sclerosis, psoriatic arthritis, Reiter's syndrome, relapsing polychondritis, sarcoidosis, Sjogren's syndrome, systemic lupus erythematosus, ulcerative colitis, vasculitis, vitiligo, Vogt Koyanagi Harada syndrome.
  • Syndromes confined primarily to the eye are, for instance, acute multifocal placoid pigmentary epitheliopathy, acute retinal necrosis, birdshot choroidopathy, Fuch's heterochromic cyclitis, glaucomatocyclitic crisis, lens-induced uveitis, multifocal choroiditis, pars planitis, serpiginous choroiditis, sympathetic ophthalmia, and trauma.
  • Examples for inflammatory diseases of the larynx are gastroesophageal (laryngopharyngeal) reflux disease, pediatric laryngitis, acute laryngeal infections of adults, chronic (granulomatous) diseases, allergic, immune, and idiopathic disorders and miscellaneous inflammatory conditions.
  • Pediatric laryngitis is known as acute (viral or bacterial) infection such as laryngotracheitis (croup), supraglottitis (epiglottitis), diphtheria, and noninfectious causes are for example spasmodic croup and traumatic laryngitis.
  • Acute laryngeal infections of adults are, for instance, viral laryngitis, common upper respiratory infection, laryngotracheitis, herpes simplex, bacterial laryngitis, supraglottitis, laryngeal abscess, and gonorrhea.
  • Chronic (granulomatous) diseases can be selected from the group comprising bacterial diseases, tuberculosis, leprosy, scleroma, actinomycosis, tularemia, glanders, spirochetal (syphilis) diseases, mycotic (fungal) diseases, candidiasis, blastomycosis, histoplasmosis, coccidiomycosis, aspergillosis, idiopathic diseases, sarcoidosis, and Wegener's granulomatosis.
  • bacterial diseases tuberculosis, leprosy, scleroma, actinomycosis, tularemia, glanders, spirochetal (syphilis) diseases, mycotic (fungal) diseases, candidiasis, blastomycosis, histoplasmosis, coccidiomycosis, aspergillosis, idiopathic diseases, sarcoidosis, and Wegener's
  • Allergic, immune, and idiopathic disorders are, for example, hypersensitivity reactions, angioedema, Stevens-Johnson syndrome, immune and idiopathic disorders, infections of the immunocompromised host, rheuatoid arthritis, systeic lupus erythematosus, cicatricial pemphigoid, relapsing polychondritis, Sjogren's syndrome, and amyloidosis.
  • Miscellaneous inflammatory conditions are, for instance, parasitic infections, trichinosis, leishmaniasis, schistosomiasis, syngamus laryngeus, inhalation laryngitis, acute (thermal) injury, pollution and inhalant allergy, carcinogens, radiation injury, radiation laryngitis, radionecrosis, vocal abuse, vocal-cord hemorrhage, muscle tension dysphonias, and contact ulcer and granuloma.
  • inventive compounds according to the general formula (I) as well as pharmaceutically acceptable salts thereof are also useful for treatment of stroke.
  • the compounds according to the general formula (I) as well as pharmaceutically acceptable salts thereof are used as an inhibitor for a protein kinase, preferably as an inhibitor for a cellular protein kinase.
  • said cellular protein kinase consists of Cyclin- dependent protein kinases (CDKs).
  • the cyclin-dependent protein kinase can be selected from the group comprising:
  • said cyclin-dependent protein kinase is CDK7.
  • CDK7 said cyclin-dependent protein kinase is CDK7.
  • the compounds according to the general formula (I) as well as pharmaceutically acceptable salts thereof selectively inhibit CDK7 in comparison to other protein kinases and in comparison to other cyclin-dependent protein kinases.
  • the compounds according to the general formula (I) as well as pharmaceutically acceptable salts thereof are used as selective inhibitors for CDK7.
  • a kinase “inhibitor” refers to any compound capable of downregulating, decreasing, suppressing or otherwise regulating the amount and/or activity of a kinase. Inhibition of these kinases can be achieved by any of a variety of mechanisms known in the art, including, but not limited to binding directly to the kinase polypeptide, denaturing or otherwise inactivating the kinase, or inhibiting the expression of the gene (e.g., transcription to mRNA, translation to a nascent polypeptide, and/or final polypeptide modifications to a mature protein), which encodes the kinase.
  • kinase inhibitors may be proteins, polypeptides, nucleic acids, small molecules, or other chemical moieties.
  • inhibiting refers to the ability of a compound to downregulate, decrease, reduce, suppress, inactivate, or inhibit at least partially the activity of an enzyme, or the expression of an enzyme or protein and/or the virus replication.
  • a method for preventing and/or treating infectious diseases, including opportunistic diseases, in a mammal, especially in a human comprises administering to the mammal an amount of at least one compound according to the general formula (I), effective to prevent and/or treat said infectious diseases, including opportunistic diseases.
  • the infectious diseases, including opportunistic diseases are virally induced infectious diseases.
  • the virally induced infectious diseases, including opportunistic diseases are caused by retroviruses, hepadnaviruses, herpesviruses, flaviviridae, and/or adenoviruses.
  • the retroviruses are selected from lentiviruses or oncoretroviruses, wherein the lentivirus is selected from the group comprising: HIV-1 , HIV-2, FIV, BIV, SIVs, SHIV, CAEV, VMV or EIAV, preferably HIV-1 or HIV-2 and wherein the oncoretrovirus is selected from the group consisting of: HTLV-I, HTLV-II or BLV.
  • the hepadnavirus is selected from HBV, GSHV or WHV, preferably HBV
  • the herpesivirus is selected from the group comprising: HSV I, HSV II, EBV, VZV, HCMV or HHV 8, preferably HCMV
  • the flaviviridae is selected from HCV, West nile or Yellow Fever.
  • methods for preventing and/or treating infectious diseases including opportunistic diseases, prion diseases, immunological diseases, autoimmune diseases, cardiovascular diseases, cell proliferative diseases, inflammation, erectile dysfunction and stroke in a mammal, especially in a human comprise administering to the mammal an amount of at least one compound according to the general formula (I) and/or pharmaceutically acceptable salts thereof, effective to prevent and/or treat said infectious diseases including opportunistic diseases, prion diseases, immunological diseases, autoimmune diseases, cardiovascular diseases, cell proliferative diseases, inflammation, erectile dysfunction and stroke.
  • the specific diseases addressed as infectious diseases including opportunistic diseases, prion diseases, immunological diseases, autoimmune diseases, cardiovascular diseases, cell proliferative diseases, inflammation, erectile dysfunction and stroke are selected from the groups disclosed above.
  • HIV compounds according to the general formula (I) may be administered in combination with anti-retroviral drugs, selected from the following five classes:
  • NRTIs Nucleoside reverse transcriptase inhibitors
  • NRTIs Non-nucleoside reverse transcriptase inhibitors
  • another aspect of the present invention relates to drug combinations comprising at least one inventive compound according to general formula (I) and/or pharmaceutically acceptable salts thereof together with at least one anti-retroviral drug, especially at least one of the drugs mentioned above.
  • the compounds of the present invention are used for the manufacture of a pharmaceutical formulation for prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, immunological diseases, autoimmune diseases, cardiovascular diseases, cell proliferative diseases, inflammation, erectile dysfunction and stroke.
  • infectious diseases including opportunistic diseases, immunological diseases, autoimmune diseases, cardiovascular diseases, cell proliferative diseases, inflammation, erectile dysfunction and stroke.
  • compositions or formulations according to the present invention comprise at least one compound according to the present invention as an active ingredient together with at least one pharmaceutically acceptable (i.e. non-toxic) carrier, excipient and/or diluent.
  • pharmaceutically acceptable (i.e. non-toxic) carrier, excipient and/or diluent i.e. non-toxic carrier, excipient and/or diluent.
  • the pharmaceutical compositions of the present invention can be prepared in a conventional solid or liquid carrier or diluent and a conventional pharmaceutically-made adjuvant at suitable dosage level in a known way.
  • the preferred preparations are adapted for oral application.
  • These administration forms include, for example, pills, tablets, film tablets, coated tablets, capsules, powders and deposits.
  • the present invention also includes pharmaceutical preparations for parenteral application, including dermal, intradermal, intragastral, intracutan, intravasal, intravenous, intramuscular, intraperitoneal, intranasal, intravaginal, intrabuccal, percutan, rectal, subcutaneous, sublingual, topical, or transdermal application, which preparations in addition to typical vehicles and/or diluents contain at least one compound according to the present invention and/or a pharmaceutical acceptable salt thereof as active ingredient.
  • compositions according to the present invention containing at least one compound according to the present invention and/or a pharmaceutical acceptable salt thereof as active ingredient will typically be administered together with suitable carrier materials selected with respect to the intended form of administration, i.e. for oral administration in the form of tablets, capsules (either solid filled, semi-solid filled or liquid filled), powders for constitution, gels, elixirs, dispersable granules, syrups, suspensions, and the like, and consistent with conventional pharmaceutical practices.
  • suitable carrier materials selected with respect to the intended form of administration, i.e. for oral administration in the form of tablets, capsules (either solid filled, semi-solid filled or liquid filled), powders for constitution, gels, elixirs, dispersable granules, syrups, suspensions, and the like, and consistent with conventional pharmaceutical practices.
  • the active drug component may be combined with any oral non-toxic pharmaceutically acceptable carrier, preferably with an inert carrier like lactose, starch, sucrose, cellulose, magnesium stearate, dicalcium phosphate, calcium sulfate, talc, mannitol, ethyl alcohol (liquid filled capsules) and the like.
  • an inert carrier like lactose, starch, sucrose, cellulose, magnesium stearate, dicalcium phosphate, calcium sulfate, talc, mannitol, ethyl alcohol (liquid filled capsules) and the like.
  • suitable binders, lubricants, disintegrating agents and coloring agents may also be incorporated into the tablet or capsule.
  • Powders and tablets may contain about 5 to about 95-weight % of the pyrazolo[1 ,5- a][1 ,3,5]triazine derivatives according to the general formula (I) or analogues compound thereof or the respective pharmaceutically active salt as active ingredient.
  • Suitable binders include starch, gelatin, natural sugars, corn sweeteners, natural and synthetic gums such as acacia, sodium alginate, carboxymethylcellulose, polyethylene glycol and waxes.
  • suitable lubricants there may be mentioned boric acid, sodium benzoate, sodium acetate, sodium chloride, and the like.
  • Suitable disintegrants include starch, methylcellulose, guar gum, and the like. Sweetening and flavoring agents as well as preservatives may also be included, where appropriate. The disintegrants, diluents, lubricants, binders etc. are discussed in more detail below.
  • compositions of the present invention may be formulated in sustained release form to provide the rate controlled release of any one or more of the components or active ingredients to optimise the therapeutic effect(s), e.g. antihistaminic activity and the like.
  • Suitable dosage forms for sustained release include tablets having layers of varying disintegration rates or controlled release polymeric matrices impregnated with the active components and shaped in tablet form or capsules containing such impregnated or encapsulated porous polymeric matrices.
  • Liquid form preparations include solutions, suspensions, and emulsions.
  • Liquid form preparations may also include solutions for intranasal administration.
  • Aerosol preparations suitable for inhalation may include solutions and solids in powder form, which may be present in combination with a pharmaceutically acceptable carrier such as an inert, compressed gas, e.g. nitrogen.
  • a pharmaceutically acceptable carrier such as an inert, compressed gas, e.g. nitrogen.
  • a low melting wax such as a mixture of fatty acid glycerides like cocoa butter is melted first, and the active ingredient is then dispersed homogeneously therein e.g. by stirring. The molten, homogeneous mixture is then poured into conveniently sized moulds, allowed to cool, and thereby solidified.
  • solid form preparations which are intended to be converted, shortly before use, to liquid form preparations for either oral or parenteral administration.
  • liquid forms include solutions, suspensions, and emulsions.
  • the compounds according to the present invention may also be delivered transdermally.
  • the transdermal compositions may have the form of a cream, a lotion, an aerosol and/or an emulsion and may be included in a transdermal patch of the matrix or reservoir type as is known in the art for this purpose.
  • capsule refers to a specific container or enclosure made e.g. of methylcellulose, polyvinyl alcohols, or denatured gelatins or starch for holding or containing compositions comprising the active ingredient(s).
  • Capsules with hard shells are typically made of blended of relatively high gel strength gelatins from bones or pork skin.
  • the capsule itself may contain small amounts of dyes, opaquing agents, plasticisers and/or preservatives.
  • a compressed or moulded solid dosage form which comprises the active ingredients with suitable diluents.
  • the tablet may be prepared by compression of mixtures or granulations obtained by wet granulation, dry granulation, or by compaction well known to a person of ordinary skill in the art.
  • Oral gels refer to the active ingredients dispersed or solubilised in a hydrophilic semisolid matrix.
  • Powders for constitution refers to powder blends containing the active ingredients and suitable diluents which can be suspended e.g. in water or in juice.
  • suitable diluents are substances that usually make up the major portion of the composition or dosage form.
  • Suitable diluents include sugars such as lactose, sucrose, mannitol, and sorbitol, starches derived from wheat, corn rice, and potato, and celluloses such as microcrystalline cellulose.
  • the amount of diluent in the composition can range from about 5 to about 95 % by weight of the total composition, preferably from about 25 to about 75 weight %, and more preferably from about 30 to about 60 weight %.
  • disintegrants refers to materials added to the composition to support break apart (disintegrate) and release the pharmaceutically active ingredients of a medicament.
  • Suitable disintegrants include starches, "cold water soluble" modified starches such as sodium carboxymethyl starch, natural and synthetic gums such as locust bean, karaya, guar, tragacanth and agar, cellulose derivatives such as methylcellulose and sodium carboxymethylcellulose, microcrystalline celluloses, and cross-linked microcrystalline celluloses such as sodium croscaramellose, alginates such as alginic acid and sodium alginate, clays such as bentonites, and effervescent mixtures.
  • the amount of disintegrant in the composition may range from about 2 to about 20 weight % of the composition, more preferably from about 5 to ca. 10 weight %.
  • Binders are substances which bind or "glue” together powder particles and make them cohesive by forming granules, thus serving as the "adhesive" in the formulation. Binders add cohesive strength already available in the diluent or bulking agent. Suitable binders include sugars such as sucrose, starches derived from wheat corn rice and potato, natural gums such as acacia, gelatin and tragacanth, derivatives of seaweed such as alginic acid, sodium alginate and ammonium calcium alginate, cellulose materials such as methylcellulose, sodium carboxymethylcellulose and hydroxypropylmethylcellulose, polyvinylpyrrolidone, and inorganic compounds such as magnesium aluminum silicate. The amount of binder in the composition may range from about 2 to about 20 weight % of the composition, preferably from about 3 to about 10 weight %, and more preferably from about 3 to about 6 weight %.
  • Lubricants refer to a class of substances which are added to the dosage form to enable the tablet granules etc. after being compressed to release from the mould or die by reducing friction or wear.
  • Suitable lubricants include metallic stearates such as magnesium stearate, calcium stearate, or potassium stearate, stearic acid, high melting point waxes, and other water soluble lubricants such as sodium chloride, sodium benzoate, sodium acetate, sodium oleate, polyethylene glycols and D,L-leucine. Lubricants are usually added at the very last step before compression, since they must be present at the surface of the granules.
  • the amount of lubricant in the composition may range from about 0.2 to about 5 weight % of the composition, preferably from about 0.5 to about 2 weight %, and more preferably from about 0.3 to about 1 .5 weight % of the composition.
  • Glidents are materials that prevent caking of the components of the pharmaceutical composition and improve the flow characteristics of granulate so that flow is smooth and uniform. Suitable glidents include silicon dioxide and talc.
  • the amount of glident in the composition may range from about 0.1 to about 5 weight % of the final composition, preferably from about 0.5 to about 2 weight %.
  • Coloring agents are excipients that provide coloration to the composition or the dosage form. Such excipients can include food grade dyes adsorbed onto a suitable adsorbent such as clay or aluminum oxide.
  • the amount of the coloring agent may vary from about 0.1 to about 5 weight % of the composition, preferably from about 0.1 to about 1 weight %.
  • CDCI3 deuterated chloroform
  • cHex cyclohexane
  • DCM diichloromethane
  • DIPEA N-ethyl-N,N-diisopropylamine
  • DMF dimethylformamide
  • DMSO dimethyl sulfoxide
  • eq equivalent
  • ES electrospray
  • EtOAc ethyl acetate
  • EtOH ethanol
  • mCPBA 3- chlorobenzoperoxoic acid
  • MeOH methanol
  • MeCN acetonitrile
  • MS mass spectrometry
  • NMR nuclear magnetic resonance
  • Pd(dppf)Cl2 [1 ,1 '- bis(diphenylphosphino)ferrocene]dichloro palladium(ll) complex with dichloromethane
  • iPrOH iso-propanol
  • RT room temperature
  • sat room temperature
  • aq. saturated aqueous
  • S1O 2 siliconca gel
  • TFA trifluoroacetic acid
  • THF tetrahydrofuran
  • KHMDS potassium hexamethyldisilazide
  • FRET-signal fluorescence resonance energy transfer
  • MBP substrat myelin basic protein
  • ATP adenosine triphosphate
  • HEPES 4-(2- hydroxyethyl)-1 -piperazineethanesulfonic acid
  • EGTA ethylene glycol tetraacetic acid
  • EDTA ethylenediaminetetraacetic acid
  • DTT dithiothreitol
  • CycH cyclin-H
  • CycA (cyclin-A), MAT1 (mating type gene 1 ), PYBOP (benzotriazole-1 -yl- oxytripyrrolidinophosphonium hexafluorophosphate), NMP (N-Methyl-2-pyrrolidone), Pd-PEPPSI-IPent (dichloro[1 ,3-bis(2,6-di-3-pentylphenyl)imidazol-2-ylidene](3- chloropyridyl)palladium(ll)).
  • intermediate (IV) (raw, prepared from 15 g intermediate (III)) in 10.5 ml (0.101 mol) benzyl alcohol and 20 ml MeCN 46.7 ml of DIPEA (0.268 mmol) were added and the reaction mixture was stirred over night. Additional 7.0 ml of the alcohol and 23.4 ml of DIPEA were added as the reaction was not completed.
  • the reaction mixture was stirred for another 4 h, diluted with ethyl acetate and washed with 2M NaOH. The aqueous phase was extracted twice with ethyl acetate. The combined organic phases were washed with brine, dried over MgSO4, filtered and evaporated.
  • the product was purified by column chromatography using 330g silica gel and a cyclohexane / ethyl acetate gradient to give the desired product as reddish oil.
  • Vl-a 60 mg (0.167 mmol) methylsulfone (Vl-a) were added to a soltution of tert-butyl 3- hydroxypiperidine-1 -carboxylate (101 mg, 0.501 mmol) and KHMDS (1 M in THF, 0.501 mmol, 501 ⁇ ) in DMF and stirred over night at 60 °C.
  • the reaction mixture was diluted with ethyl acetate, washed with 10% aqueous NaHCO3 and brine, dried with MgSO 4 , filtered and concentrated in vacuo.
  • the Boc-protecting group was removed in TFA and the pure compound (Vll-c) was obtained after RP-HPLC using a water/acetonitrile (0.1 % TFA) gradient.
  • Vll-b (Vll-v) and (Vll-af) - (Vll-cd) were prepared from the related methylsulfones (VI) according to method C (in some cases NaH was used as base instead of KHMDS).
  • ester (XXIV) 2.0 g (5.22 mmol) of ester (XXIV) were dissolved in 40 ml THF and 25 ml 0.5 M NaOH. The mixture was stirred at room temperature for 5 h. Water was added and the mixture was extracted three times with TBME. The aqueous phase was adjusted to pH 5 using 5 % citric acid and extracted with ethyl acetate. The second organic phase was dried and evaporated. 1 .5 g of the title compound (XXV) were obtained.
  • the Boc-protected intermediate was dissolved in 1 ml dichloromethane at 0 °C. 10 equivalents trifluoroacetic acid were added and the reaction mixture was stirred over night. The reaction mixture was evaporated and the residue was purified on silica gel, eluting with 90/10 chloroform/methanol. 34 mg of the title product was obtained.

Abstract

La présente invention concerne des dérivés pyrazolo[1,5-a][1,3,5]triazine et/ou des sels pharmaceutiquement acceptables et des compositions pharmaceutiquement acceptables de ces derniers, l'utilisation de ces dérivés en tant qu'agents pharmaceutiquement actifs, notamment pour la prophylaxie et/ou le traitement de maladies infectieuses, y compris les maladies opportunistes, les maladies immunologiques, les maladies cardiovasculaires, les maladies liées à une prolifération cellulaire, l'inflammation, la dysérection et l'accident vasculaire cérébral, ainsi que des compositions pharmaceutiques contenant au moins un desdits dérivés pyrazolo[1,5-a][1,3,5]triazine et/ou leurs sels pharmaceutiquement acceptables. L'invention porte également sur l'utilisation des dérivés pyrazolo[1,5-a][1,3,5]triazine en tant qu'inhibiteurs d'une protéine kinase.
PCT/EP2013/054225 2012-03-01 2013-03-01 Dérivés pyrazolo-triazine pharmaceutiquement actifs WO2013128029A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US14/389,946 US9096608B2 (en) 2012-03-01 2013-03-01 Pharmaceutically active pyrazolo-triazine derivatives

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20120157722 EP2634189A1 (fr) 2012-03-01 2012-03-01 Dérivés de pyrazolo-triazine en tant qu'inhibiteurs sélectifs de kinases dépendantes de la cycline
EP12157722.5 2012-03-01

Publications (1)

Publication Number Publication Date
WO2013128029A1 true WO2013128029A1 (fr) 2013-09-06

Family

ID=47845989

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2013/054225 WO2013128029A1 (fr) 2012-03-01 2013-03-01 Dérivés pyrazolo-triazine pharmaceutiquement actifs

Country Status (3)

Country Link
US (1) US9096608B2 (fr)
EP (1) EP2634189A1 (fr)
WO (1) WO2013128029A1 (fr)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015154022A1 (fr) * 2014-04-05 2015-10-08 Syros Pharmaceuticals, Inc. Inhibiteurs de kinase cycline-dépendante 7 (cdk7)
KR20170077168A (ko) 2014-10-31 2017-07-05 우베 고산 가부시키가이샤 치환 디히드로피롤로피라졸 화합물
KR20180018661A (ko) 2015-06-15 2018-02-21 우베 고산 가부시키가이샤 치환 디히드로피롤로피라졸 유도체
US9932344B2 (en) 2014-02-21 2018-04-03 Cancer Research Technology Limited Pyrazolo[1,5-A]pyrimidine-5,7-diamine compounds as CDK inhibitors and their therapeutic use
US10059690B2 (en) 2014-04-04 2018-08-28 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
WO2018185120A1 (fr) 2017-04-05 2018-10-11 Curovir Ab Composés hétéroaromatiques utiles en thérapie
US10407429B2 (en) 2015-06-24 2019-09-10 Curovir Ab Pyrazolo[1,5-a]triazin-4-amine derivatives useful in therapy
WO2019197549A1 (fr) * 2018-04-11 2019-10-17 Qurient Co., Ltd. Dérivés de pyrazolo-triazine et/ou de pyrazolo-pyrimidine en tant qu'inhibiteurs sélectifs de kinase dépendante de la cycline
WO2019197546A1 (fr) * 2018-04-11 2019-10-17 Qurient Co., Ltd. Dérivés de pyrazolotriazine et/ou de pyrazolopyrimidine pharmaceutiquement actifs
WO2020100944A1 (fr) 2018-11-14 2020-05-22 宇部興産株式会社 Dérivé de dihydropyrrolopyrazole
US11186576B2 (en) 2015-03-09 2021-11-30 Aurigene Discovery Technologies Limited Pyrazolo[1,5-A][1,3,5]triazine and pyrazolo[1,5-A]pyrimidine derivatives as CDK inhibitors
CN114929708A (zh) * 2019-12-16 2022-08-19 卡里克治疗有限公司 4-[[(7-氨基吡唑并[1,5-a]嘧啶-5-基)氨基]甲基]哌啶-3-醇化合物以及它们的治疗用途
WO2023001061A1 (fr) * 2021-07-17 2023-01-26 Jingrui Biopharma Co., Ltd. Inhibiteurs sélectifs de cdk7 utiles en tant qu'agents anticancéreux
WO2023094310A1 (fr) * 2021-11-23 2023-06-01 Origenis Gmbh Dérivés de pyrazolotriazine utiles en tant qu'inhibiteurs de cdk9
RU2809779C2 (ru) * 2018-04-11 2023-12-18 Кьюриент Ко., Лтд. Производные пиразолотриазина и/или пиразолопиримидина в качестве селективного ингибитора циклинзависимой киназы
US11857552B2 (en) 2017-09-20 2024-01-02 Carrick Therapeutics Limited 4-[[(7-aminopyrazolo[1,5-a]pyrimidin-5-yl)amino]methyl]piperidin-3-ol compounds as CDK inhibitors

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3112443A1 (fr) 2018-09-12 2020-03-19 The Governing Council Of The University Of Toronto Composes et procedes de traitement d'infections par des nematodes
US11517568B2 (en) 2018-09-12 2022-12-06 The Governing Council Of The University Of Toronto Compounds and methods for treating nematode infections
CN115152761B (zh) * 2022-06-24 2023-05-02 吉安职业技术学院 藻类抑制剂及制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US615968A (en) 1898-12-13 Apparatus for treating ores
WO2005077954A2 (fr) * 2004-02-11 2005-08-25 Schering Corporation Nouvelles pyrazolopyrimidines tenant lieu d'inhibiteurs de la kinase dependant de la cycline
WO2005082908A1 (fr) * 2004-02-25 2005-09-09 Schering Corporation Pyrazolotriazines en tant qu'inhibiteurs de kinase
WO2010103486A1 (fr) * 2009-03-11 2010-09-16 Centre National De La Recherche Scientifique Derives de pyrazolo[1,5-a]-1,3,5-triazines, leur preparation et leur application en therapeutique

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US615968A (en) 1898-12-13 Apparatus for treating ores
WO2005077954A2 (fr) * 2004-02-11 2005-08-25 Schering Corporation Nouvelles pyrazolopyrimidines tenant lieu d'inhibiteurs de la kinase dependant de la cycline
WO2005082908A1 (fr) * 2004-02-25 2005-09-09 Schering Corporation Pyrazolotriazines en tant qu'inhibiteurs de kinase
WO2010103486A1 (fr) * 2009-03-11 2010-09-16 Centre National De La Recherche Scientifique Derives de pyrazolo[1,5-a]-1,3,5-triazines, leur preparation et leur application en therapeutique

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
A.L. SIMPLICIO, MOLECULES, vol. 13, 2008, pages 519 - 547
J.P. KRISE; R. OLIYAI: "Prodrugs of Amines", BIOTECHNOLOGY: PHARMACEUTICAL ASPECTS, vol. V, 2007, pages 801 - 831
NEKHAI ET AL., BIOCHEM. J., vol. 364, 2002, pages 649 - 657
POPOWYCZ F ET AL: "Synthesis and antiproliferative evaluation of pyrazolo[1,5-a]-1,3,5-triazine myoseverin derivatives", BIOORGANIC & MEDICINAL CHEMISTRY, PERGAMON, GB, vol. 17, no. 9, 10 March 2009 (2009-03-10), pages 3471 - 3478, XP026022791, ISSN: 0968-0896, [retrieved on 20090310], DOI: 10.1016/J.BMC.2009.03.007 *
POPOWYCZ FLORENCE ET AL: "Pyrazolo[1,5-a]-1,3,5-triazine as a Purine Bioisostere: Access to Potent Cyclin-Dependent Kinase Inhibitor (R)-Roscovitine Analogue", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 52, no. 3, 1 July 2009 (2009-07-01), pages 655 - 663, XP002548292, ISSN: 0022-2623, [retrieved on 20090107], DOI: 10.1021/JM801340Z *
T. HIGUCHI; W. STELLA: "Pro-drugs as Novel Drug Delivery Systems", ACS SYMPOSIUM SERIES, vol. 14, 1975
TAMRAKAR ET AL., JOURNAL OF VIROLOGY, vol. 79, 2005, pages 15477 - 15493
YOUNG KYEUNG KIM, EMBO I, vol. 25, 2006, pages 3596 - 3604

Cited By (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11566029B2 (en) 2014-02-21 2023-01-31 Ip2Ipo Innovations Limited Pyrazolo[1,5-a]pyrimidine-5,7-diamine compounds as CDK inhibitors and their therapeutic use
US10927119B2 (en) 2014-02-21 2021-02-23 Ip2Ipo Innovations Limited Pyrazolo[1,5-a]pyrimidine-5,7-diamine compounds as CDK inhibitors and their therapeutic use
US9932344B2 (en) 2014-02-21 2018-04-03 Cancer Research Technology Limited Pyrazolo[1,5-A]pyrimidine-5,7-diamine compounds as CDK inhibitors and their therapeutic use
US10414772B2 (en) 2014-02-21 2019-09-17 Imperial Innovations Limited Pyrazolo[1,5-A]pyrimidine-5,7-diamine compounds as CDK inhibitors and their therapeutic use
US10106526B2 (en) 2014-04-04 2018-10-23 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
US10059690B2 (en) 2014-04-04 2018-08-28 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
EP3805218A1 (fr) * 2014-04-05 2021-04-14 Syros Pharmaceuticals, Inc. Inhibiteurs de la kinase cycline-dépendante 7 (cdk7)
US10336760B2 (en) 2014-04-05 2019-07-02 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
WO2015154022A1 (fr) * 2014-04-05 2015-10-08 Syros Pharmaceuticals, Inc. Inhibiteurs de kinase cycline-dépendante 7 (cdk7)
US10968238B2 (en) 2014-10-31 2021-04-06 Ube Industries, Ltd. Substituted dihydropyrrolopyrazole compound
KR20170077168A (ko) 2014-10-31 2017-07-05 우베 고산 가부시키가이샤 치환 디히드로피롤로피라졸 화합물
US10131679B2 (en) 2014-10-31 2018-11-20 Ube Industries, Ltd. Substituted dihydropyrrolopyrazole compound
US11186576B2 (en) 2015-03-09 2021-11-30 Aurigene Discovery Technologies Limited Pyrazolo[1,5-A][1,3,5]triazine and pyrazolo[1,5-A]pyrimidine derivatives as CDK inhibitors
US10273252B2 (en) 2015-06-15 2019-04-30 Ube Industries, Ltd. Substituted dihydropyrrolopyrazole derivative
US10894798B2 (en) 2015-06-15 2021-01-19 Ube Industries, Ltd. Substituted dihydropyrrolopyrazole derivative
KR20180018661A (ko) 2015-06-15 2018-02-21 우베 고산 가부시키가이샤 치환 디히드로피롤로피라졸 유도체
US10407429B2 (en) 2015-06-24 2019-09-10 Curovir Ab Pyrazolo[1,5-a]triazin-4-amine derivatives useful in therapy
US11001587B2 (en) 2017-04-05 2021-05-11 Curovir Ab Substituted indazoles as phosphatidylinositol kinase inhibitors
WO2018185120A1 (fr) 2017-04-05 2018-10-11 Curovir Ab Composés hétéroaromatiques utiles en thérapie
US11857552B2 (en) 2017-09-20 2024-01-02 Carrick Therapeutics Limited 4-[[(7-aminopyrazolo[1,5-a]pyrimidin-5-yl)amino]methyl]piperidin-3-ol compounds as CDK inhibitors
IL299105A (en) * 2018-04-11 2023-02-01 Lead Discovery Center Gmbh Pharmacologically active history of pyrazolo-trizine and/or pyrazolo-pyrimidine
AU2019250504B2 (en) * 2018-04-11 2023-05-18 Lead Discovery Center Gmbh Pharmaceutically active pyrazolo-triazine and/or pyrazolo-pyrimidine derivatives
WO2019197549A1 (fr) * 2018-04-11 2019-10-17 Qurient Co., Ltd. Dérivés de pyrazolo-triazine et/ou de pyrazolo-pyrimidine en tant qu'inhibiteurs sélectifs de kinase dépendante de la cycline
RU2818563C2 (ru) * 2018-04-11 2024-05-02 Кьюриент Ко., Лтд. Фармацевтически активные производные пиразолотриазина и/или пиразолопиримидина
US11945822B2 (en) 2018-04-11 2024-04-02 Qurient Co., Ltd. Pyrazolo-triazine and/or pyrazolo-pxrimidine derivatives as selective inhibitor of cyclin dependent kinase
JP2021521129A (ja) * 2018-04-11 2021-08-26 キュリエント カンパニー， リミテッド 薬学的に活性なピラゾロ−トリアジン誘導体および／またはピラゾロ−ピリミジン誘導体
WO2019197546A1 (fr) * 2018-04-11 2019-10-17 Qurient Co., Ltd. Dérivés de pyrazolotriazine et/ou de pyrazolopyrimidine pharmaceutiquement actifs
JP2021521120A (ja) * 2018-04-11 2021-08-26 キュリエント カンパニー， リミテッド サイクリン依存性キナーゼの選択的インヒビターとしてのピラゾロ−トリアジン誘導体および／またはピラゾロ−ピリミジン誘導体
US11858937B2 (en) 2018-04-11 2024-01-02 Qurient Co., Ltd. Substituted pyrazolo[1,5-a]pyrimidines and pyrazolo[1,5-a][1,3,5]triazines as CDK inhibitors
IL277770B1 (en) * 2018-04-11 2023-09-01 Qurient Co Ltd History of pyrazolo-triazine and/or pyrazolo-pyrimidine as selective inhibitors of cyclin-dependent kinase
AU2019250507B2 (en) * 2018-04-11 2023-09-28 Lead Discovery Center Gmbh Pyrazolo-triazine and/or pyrazolo-pyrimidine derivatives as selective inhibitor of cyclin dependent kinase
IL299105B1 (en) * 2018-04-11 2023-10-01 Lead Discovery Center Gmbh Pharmacologically active history of pyrazolo-trizine and/or pyrazolo-pyrimidine
RU2809779C2 (ru) * 2018-04-11 2023-12-18 Кьюриент Ко., Лтд. Производные пиразолотриазина и/или пиразолопиримидина в качестве селективного ингибитора циклинзависимой киназы
JP7406501B2 (ja) 2018-04-11 2023-12-27 キュリエント カンパニー， リミテッド 薬学的に活性なピラゾロ－トリアジン誘導体および／またはピラゾロ－ピリミジン誘導体
WO2020100944A1 (fr) 2018-11-14 2020-05-22 宇部興産株式会社 Dérivé de dihydropyrrolopyrazole
CN114929708A (zh) * 2019-12-16 2022-08-19 卡里克治疗有限公司 4-[[(7-氨基吡唑并[1,5-a]嘧啶-5-基)氨基]甲基]哌啶-3-醇化合物以及它们的治疗用途
WO2023001061A1 (fr) * 2021-07-17 2023-01-26 Jingrui Biopharma Co., Ltd. Inhibiteurs sélectifs de cdk7 utiles en tant qu'agents anticancéreux
WO2023094310A1 (fr) * 2021-11-23 2023-06-01 Origenis Gmbh Dérivés de pyrazolotriazine utiles en tant qu'inhibiteurs de cdk9

Also Published As

Publication number Publication date
US20150111873A1 (en) 2015-04-23
EP2634189A1 (fr) 2013-09-04
US9096608B2 (en) 2015-08-04

Similar Documents

Publication Publication Date Title
AU2013224848B2 (en) Pyrazolo - triazine derivatives as selective cyclin- dependent kinase inhibitors
WO2013128029A1 (fr) Dérivés pyrazolo-triazine pharmaceutiquement actifs
AU2011231975B2 (en) Pharmaceutically active disubstituted triazine derivatives
CA2826464C (fr) Derives de triazine disubstitues pharmaceutiquement actifs
EP2681193B1 (fr) Dérivés de pyridine disubstitués pharmaceutiquement actifs
WO2021175270A1 (fr) Nouvel inhibiteur de hpk1, son procédé de préparation et son application
JP6619796B2 (ja) Ｍｉｆ阻害剤
CA2897459C (fr) Derives d'amides heterocycliques utilises comme antagonistes du recepteur p2x7
AU2022296371A1 (en) Sulfoximide substituted indazole irak4 kinase inhibitor, preparation method therefor, and use thereof
AU2005245536A1 (en) Substituted azachinazolines having an antiviral action
WO2006089874A1 (fr) BENZO[2,3]AZÉPINO[4,5-b]INDOL-6-ONES

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13708770

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 14389946

Country of ref document: US

122 Ep: pct application non-entry in european phase

Ref document number: 13708770

Country of ref document: EP

Kind code of ref document: A1